NATIONAL CANCER POLICY FORUM

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop

Convened by the National Cancer Policy Forum in collaboration with the Program on Computing Research, Technologies, and Systems

Keck Center – Keck 100
500 5th St, NW
Washington, DC 20001

Link to view the live webcast:
Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care | National Academies

NATIONAL ACADEMIES Sciences Engineering Medicine

NATIONAL CANCER POLICY FORUM

Workshop Location

Keck Center
500 Fifth St., N.W.
Washington, DC 20001

Parking: Entrance to the building's parking garage is in the rear of the building on 6th Street. When entering, be ready to present your identification card and tell the guard the name of the meeting you are attending.

By Metro's Green or Yellow Line

Take Metro's Green or Yellow Line to the Gallery Place-Chinatown station.
Exit the station by following signs to Seventh and F Streets/Arena.
Turn LEFT and walk EAST on F St. N.W., two blocks past the Capital One Arena.
Turn RIGHT on to Fifth St. N.W.
Walk past the fire station parking lot. The next building on your RIGHT will be 500 Fifth St. N.W.

By Metro's Red Line

Take Metro's Red Line to the Judiciary Square station.
Exit the station by following signs to the Building Museum (F St.) exit, between Fourth and Fifth Sts. N.W.
Turn LEFT and walk WEST on F St. N.W.
Cross Fifth St. N.W. and turn LEFT.
Walk past the fire station parking lot. The next building on your RIGHT will be 500 Fifth St. N.W.

NATIONAL CANCER POLICY FORUM

Meeting Location

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop
Room 100



The Workshop on Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care will take place in **Room 100**.
The **Keck Cafeteria** is located on the **3rd floor** in the atrium.

NATIONAL CANCER POLICY FORUM

March 9, 2026

Dear Colleagues,

Welcome to the National Academies of Sciences, Engineering, and Medicine workshop on *Integrating Artificial Intelligence (AI) in Cancer Research and Care*, convened by the National Cancer Policy Forum in collaboration with the Program on Computing Research, Technologies, and Systems.

This workshop will examine the current and potential future uses of AI across healthcare and the unique needs for cancer research and care. We will also discuss current and potential policies to inform key cancer-focused strategies on how to achieve maximal value from AI innovations.

Please note that it is essential to the National Academies mission of providing evidence-based advice that participants in all our activities avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our activities are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academies.

We welcome your involvement in the workshop. Please use the microphones in the room or the chat box on our website to ask questions. Also, please mention your name and affiliation and keep your questions or comments very brief. A proceedings-in-brief from the workshop will be published by the National Academies Press and may incorporate your comments and ideas. Archived presentations and videos from the workshop will also be available on the website.

We look forward to your involvement in this workshop.

Sincerely,

Amy P. Abernethy, MD, PhD
Planning Committee Co-chair
Cofounder, Highlander Health

Samir N. Khleif, MD
Planning Committee Co-chair
Biomedical Scholar and Professor
Lombardi Comprehensive Cancer Center

NATIONAL CANCER POLICY FORUM

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop

March 9-10, 2026

National Cancer Policy Forum in collaboration with the Program on Computing Research, Technologies, and Systems

Workshop Website

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

MONDAY, MARCH 9, 2026 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Welcome and Introductory Remarks** (25 minutes) *Planning Committee Co-Chairs:* *Amy Abernethy, Highlander Health* *Samir Khleif, Georgetown University Medical Center*
8:55 am	**Session 1: Keynotes** *Co-Moderators:* *Amy Abernethy, Highlander Health* *Samir Khleif, Georgetown University Medical Center* **Keynote 1: Overview of the Current State and Future Applications of AI in Health Care** (~25 minutes) • Nigam Shah, Stanford University *(Participating virtually)* **Keynote 2: Lessons from AI Integration Across Other Industries** (~25 minutes) • Dan Chu, 23andMe; Formerly at Waymo and Google
9:45am	**Transition Break (10 minutes)**
9:55 am	**Session 2: Examples of AI Applications to Address the Distinctive Needs for Cancer Care** (~1 hour, 15 minutes) *Co-Moderators:* *Amy Abernethy, Highlander Health* *Samir Khleif, Georgetown University Medical Center* *Session Objective:* Examine the distinctive nature of AI in cancer care and discuss examples of how existing and emerging AI applications can improve cancer care. **(Each speaker to present for 10 minutes)** **Scaling AI Clinical Decision Support in Oncology: Infrastructure and Policy for Treatment Matching** • Michael Hassett, Dana-Farber Cancer Institute; Harvard Medical School **AI in Cancer Care: 2 Wins, 2 Challenges** • Travis Osterman, Vanderbilt University Medical Center

	Scaling AI for Operational Impact & Return on Investment • Peter Stetson, TigerConnect *(Participating virtually)* **Panel Discussion & Audience Q&A** (~45 minutes)
11:10 am	**Transition Break** (5 minutes)
11:15 am	**Session 3: Examples of AI Applications to Address the Distinctive Needs for Cancer Research** (~1 hour, 15 minutes) *Moderator:* *Usama Fayyad, Northeastern University & Open Insights* *Session Objective:* Examine the distinctive nature of AI application in clinical cancer research and discuss examples of how existing and emerging AI applications can improve cancer research. **(Each speaker to present for 10 minutes)** **A Clinical Trialist and Professional Organization Perspective** • Etta Pisano, American College of Radiology **From Electronic Health Records to Digital Twins: Foundational Concepts for Advancing AI-Enabled Cancer Research** • Aaron Cohen, Flatiron Health **Coupling Multimodal AI and Decision Analysis for Tumor Board Support** • Eric Horvitz, Microsoft *(Participating virtually)* **Data Sharing in Digital Age: Harnessing the Power of AI for Cancer Research** • Emily Boja, National Cancer Institute *(Participating virtually)* **Panel Discussion & Audience Q&A** (~35 minutes)
12:30 pm	**Break** (1 hour)
1:30 pm	**Session 4: AI-Related Policy: Ethical and Legal Implications for Cancer Research and Care** (~1 hour, 15 minutes) *Moderator:* *Beth Karlan, University of California, Los Angeles* *Session Objective:* Review the current AI policy landscape and the evolving regulatory paradigm specific to cancer research and care, as well as legal and ethical implications. **(Each speaker to present for 10 minutes)** **A State Perspective** • Diana E. Ramos, California Surgeon General *(Participating virtually)* **US Legal & Regulatory Environment for Use of AI in Healthcare** • Danny Tobey, DLA Piper *(Participating virtually)* **Guidelines for AI in Oncology** • Jakob Kather, European Society for Medical Oncology *(Participating virtually)*

	Safety and Efficacy Perspectives in Clinical AI • Shantanu Nundy, Advisor on AI (Contractor), Office of the Food and Drug Administration Commissioner **Panel Discussion & Audience Q&A** (~35 minutes)
2:45 pm	**Transition Break** (5 minutes)
2:50 pm	**Session 5: Putting the Patient First: Ensuring AI Solutions Improve the lives of People at Risk of or Diagnosed with Cancer** (~60 minutes) *Co-Moderators:* *Cleo Ryals, Flatiron Health* *Sarah Greene, National Academy of Medicine* *Session Objective:* Discuss considerations to ensure that patients diagnosed with cancer or people at risk of cancer derive maximal value from AI. **(Each panelist to give a-5-minute introductory remark)** • Jennifer Goldsack, Digital Medicine Society (DiMe) • Cheryl Willman, Mayo Clinic • Fernanda Polubriaginof, Memorial Sloan Kettering Cancer Center • Yulin Hswen, University of Maryland **Panel Discussion & Audience Q&A** (~40 minutes)
3:50 pm	**Break (10 minutes)**
4:00 pm	**Session 6: Implications for the Cancer Research and Care Workforce** (~60 minutes) *Co-Moderators:* *Lawrence Shulman, University of Pennsylvania* *Crystal Denlinger, National Comprehensive Cancer Network* *Session Objective:* Discuss considerations to ensure that the cancer research and care workforce gets maximal value from AI. **(Each panelist to give a-5-minute introductory remark)** • Lawrence Shulman, University of Pennsylvania • Caroline Chung, MD Anderson Cancer Center • William Hall, Medical College of Wisconsin *(Participating virtually)* • Roy Rosin, First Round Capital *(Participating virtually)* **Panel Discussion & Audience Q&A** (~40 minutes)
5:00 pm	**Adjourn and Reception**

TUESDAY, MARCH 10, 2026 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Day 2 Welcome** (5 minutes) *Samir Khleif, Georgetown University Medical Center*, Planning Committee Co-Chair
8:35 am	**Session 7: What do AI Builders and Funders Need to Know to Be Able to Maximally Support Cancer Research and Care?** (~60 minutes) *Moderator:* *Amye Tevaarwerk, Mayo Clinic Comprehensive Cancer Center* *Session Objective:* Discuss what AI builders and funders need to know about cancer research and care to effectively identify and integrate policy needs to ensure that their innovations contribute meaningfully to patient-centered outcomes. **(Each panelist to give a-5-minute introductory remark)** • Amye Tevaarwerk, Mayo Clinic Comprehensive Cancer Center • Shannon Dean, St. Jude Children's Research Hospital *(Video remarks)* • Shiv Rao, Abridge *(Participating virtually)* • Krishna Yeshwant, GV *(Participating virtually)* **Panel Discussion & Audience Q&A** (~40 minutes)
9:35am	**Session 8: Envisioning the AI Future for Cancer Research and Care (~60 minutes)** *Moderator:* *Hedvig (Hedi) Hricak, Memorial Sloan Kettering Cancer Center* *Session Objective:* Discuss potential actions to inform patient needs, data/tech infrastructure, public-private partnerships, workforce development, and policy needs to ensure that AI innovations contribute positively to cancer research and care. **(Each panelist to give a-5-minute introductory remark)** • Brian Jones, Zero Prostate Cancer • Hamid Emamekhoo, University of Wisconsin-Madison • Fabio Ynoe de Moraes, Sinclair Cancer Research Institute *(Participating virtually)* • Wilfred Ngwa, ARPA-H • Praduman Jain, Vibrent Health **Panel Discussion & Audience Q&A** (~35 minutes)
10:35 am	**Break**
10:50 am	**Session 9: Reflections on the Workshop and Implications for Integrating AI in Cancer-Focused Strategies** (~40 minutes) *Co-Moderators:* *Amy Abernethy, Highlander Health* *Samir Khleif, Georgetown University Medical Center*

	Session moderators reconvene to summarize key observations and opportunities. **Sessions 1 and 2 Co-Moderators:** Samir Khleif and Amy Abernethy **Session 3 Moderator:** Usama Fayyad **Session 4 Moderator:** Beth Karlan **Session 5 Co-Moderators:** Cleo Ryals and Sarah Greene **Session 6 Co-Moderators:** Lawrence Shulman and Crystal Denlinger **Session 7 Moderator:** Amye Tevaarwerk **Session 8 Moderator:** Hedi Hricak
11:30 am	**Adjourn**

You may also scan the QR code below to submit questions and comments.
Please state your name and affiliation prior to asking a question.

NATIONAL CANCER POLICY FORUM

Current Sponsors of the National Cancer Policy Forum

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Cancer Care Centers

AVEO Oncology

Cancer Center at Illinois

Lilly

Flatiron Health

Merck

National Comprehensive Cancer Network

Novartis Oncology

Oncology Nursing Society

Partners In Health

Patient Advocate Foundation

Pfizer Inc

Vibrent Health

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

NATIONAL CANCER POLICY FORUM

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop
March 9 – 10, 2026

Planning Committee Roster

Amy Abernethy, MD, PhD
Cofounder
Highlander Health

Samir Khleif, MD
Biomedical Scholar & Professor of Oncology
Director
Center for Immunology and Immunotherapy
Director
Jeannie and Tony Loop Laboratory for Immuno-Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Member
Society for Immunotherapy of Cancer
New Research Building

Crystal Denlinger, MD, FACP
Chief Executive Officer
National Comprehensive Cancer Network

Usama Fayyad, PhD
Senior Vice Provost for AI & Data Strategy
Senior Advisor to President
Inaugural Director of Institute for Experiential AI
Chairman
Northeastern University
Open Insights

Sarah Greene, MPH
Consultant and Senior Advisor
National Academy of Medicine

Roy Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology and Hematology
Deputy Director
Yale Cancer Center and Smilow Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine

Hedvig Hricak, MD, PhD, Dr.h.cm
Carroll and Milton Petrie Chair
Department of Radiology
Gerstner Sloan-Kettering Graduate School of Biomedical Sciences
Memorial Sloan Kettering Cancer Center

Chanita Hughes Halbert, PhD
Vice Chair for Research and Professor
Department of Population and Public Health Sciences
Dr. Arthur and Priscilla Ulene Chair in Women's Cancer
Keck School of Medicine
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California

Beth Karlan, MD
Vice Chair and Professor
Department of Obstetrics and Gynecology
Director
Nancy Marks Endowed Chair in Women's Health Research
David Geffen School of Medicine at UCLA

Cleo Ryals, PhD
Senior Director
Research Sciences
Head of Health Equity Research
Flatiron Health

Lawrence Shulman MD, MACP, FASCO
Professor of Medicine
Associate Director
Special Projects
Director
Center for Global Cancer Medicine
Penn Center for Cancer Care Innovation
Abramson Cancer Center
University of Pennsylvania

Amye J. Tevaarwerk, MD
Professor of Oncology
Mayo Clinic, Rochester MN

Robert Winn, MD
Director and Lipman Chair in Oncology
VCU Massey Comprehensive Cancer Center
Senior Associate Dean for Cancer Innovation
Professor of Pulmonary Disease and Critical Care Medicine
VCU School of Medicine

NATIONAL CANCER POLICY FORUM

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop
March 9 – 10, 2026

Speaker Roster

Emily Boja, PhD
Branch Chief, Office of Data Sharing
National Cancer Institute
National Institutes of Health

Daniel Chu, MBA, MPA
Chief Product Officer
23andMe Research Institute

Caroline Chung, MD, MSc
Vice President and Chief Data & Analytics Officer
The University of Texas MD Anderson Cancer Center

Aaron Cohen, MD, MSCE
Senior Medical Director, Clinical Lead for AI and Digital Oncology
Flatiron Health
Adjunct Assistant Professor, Department of Medicine
NYU Grossman School of Medicine

Shannon M. Dean, MD, MMM
Vice President and Chief Medical Information Officer
Member, Department of Pediatrics
St. Jude Children's Research Hospital

Hamid Emamekhoo, MD, FAMIA
Associate Professor of Medicine at the Department of Medicine
University of Wisconsin-Madison
Director of Clinical Cancer Research Informatics
University of Wisconsin Carbone Cancer Center

Jennifer Goldsack, MChem, MA, MBA, OLY
Chief Executive Officer
Digital Medicine Society (DiMe)

William A. Hall, MD
Professor and Chair, Department of Radiation Oncology
Medical Director, Froedtert Radiation Oncology
Bob Uecker Endowed Chair, Department of Surgery
School of Graduate Studies
Medical College of Wisconsin

Michael Hassett, MD, MPH
Chief Quality Officer
Department of Quality & Patient Safety and Health Services Researcher
Division of Population Sciences
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Eric Horvitz, MD, PhD
Chief Scientific Officer
Director Emeritus, Microsoft Research
Microsoft

Yulin Hswen, ScD, MPH
Associate Professor
Department of Epidemiology and Biostatistics
University of Maryland
Artificial Intelligence Interdisciplinary Institute at Maryland (AIM)
College of Computer, Mathematical, and Natural Sciences

Praduman Jain, MS
Founder and Chief Executive Officer
Vibrent Health

Brian Jones, BCPA, CCHW
Certified Community Health Worker
Board Certified Patient Advocate
Zero Prostate Health Equity Task Force

Jakob Nikolas Kather, MD, MSc
Professor of Medicine and Senior Medical Oncologist
TUD Dresden University of Technology
University Hospital Dresden

Fabio Y. Moraes, MD, PhD, MBA
Neuro Oncology and Thoracic Oncology
Executive Director, Global Oncology and Innovation
Clinician-Investigator, Division of Radiation Oncology
Associate Professor, Department of Oncology
Queen's University
Kingston Health Sciences Centre
Visiting Professor, Department of Oncology and Radiology
University of São Paulo

Wilfred Ngwa, PhD
Program Manager
Advanced Research Projects Agency for Health

Shantanu Nundy, MD
Advisor on AI (Contractor)
Office of the Commissioner
U.S. Food and Drug Administration

Travis Osterman, DO, MS, FAMIA, FASCO
Associate Professor, Department of Biomedical Informatics
Associate Professor, Division of Hematology and Oncology
Associate Vice President for Research Informatics
Vanderbilt University Medical Center
Ingram Associate Professor of Cancer Research

Etta D. Pisano, MD FACR FSBI
Chief Research Officer
American College of Radiology
Adjunct Faculty in Radiology
The University of Pennsylvania
The University of North Carolina at Chapel Hill

Fernanda C. G. Polubriaginof, MD PhD, FAMIA
Senior Director, Population Health, Value and Clinical Analytics
Memorial Sloan Kettering Cancer Center

Diana E. Ramos, MD, MPH, MBA
California Surgeon General

Shiv Rao, MD
Co-Founder and Chief Executive Officer
Abridge

Roy Rosin, MBA
Board Partner
First Round Capital

Nigam H. Shah, MBBS, PhD
Professor of Medicine and of Biomedical Data Science
Chief Data Scientist, Stanford Healthcare
Associate Dean, School of Medicine
Associate Director, Stanford Center for Biomedical Informatics Research
Center for Biomedical Informatics Research, Stanford University
Technology and Digital Solutions, Stanford Healthcare
Clinical Excellence Research Center, Stanford University

Peter D. Stetson, MD, MA, FAMIA
Chief Medical Information Officer
TigerConnect

Lawrence Shulman MD, MACP, FASCO
Professor of Medicine
Associate Director
Special Projects
Director, Center for Global Cancer Medicine
Penn Center for Cancer Care Innovation
Abramson Cancer Center
University of Pennsylvania

Amye J. Tevaarwerk, MD
Professor of Oncology
Mayo Clinic, Rochester MN

Danny Tobey, MD, JD
Partner
Global Co-Chair and Chair
DLA Piper Americas AI and Data Analytics Practice

Cheryl Willman, MD
Executive Director
Mayo Clinic Cancer Programs
Director, Mayo Clinic Comprehensive Cancer Center

Krishna Yeshwant, MD, MBA
Managing Partner
GV (Google Ventures)

NATIONAL CANCER POLICY FORUM

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop
March 9 - 10, 2026

Planning Committee Biosketches

Amy Abernethy, MD, PhD (Co-Chair)
Highlander Health

Dr. Amy Abernethy is Cofounder of Highlander Health, an investment firm dedicated to advancing evidence generation and personalized healthcare for a new era of medical innovation. As an oncologist, entrepreneur, and leader in clinical research and health data science, Dr. Abernethy is passionate about breaking down barriers between clinical trials and real-world evidence, seeing both as essential parts of a unified ecosystem that delivers safer, more effective treatments to patients faster. Dr. Abernethy is at the forefront of reimagining clinical research, leveraging her lifelong work with longitudinal multimodal clinical data, artificial intelligence, and novel study designs to shift the healthcare industry towards practical integration of clinical research with everyday patient care to truly serve patients.

Previously, Dr. Abernethy served as Principal Deputy Commissioner of the U.S. Food and Drug Administration, where she led initiatives to modernize clinical evidence generation and advance personalized healthcare, while also serving as the agency's acting chief information officer. This regulatory experience directly informs Highlander Health's work in responsible AI and building modern evidence infrastructures.

More recently, Dr. Abernethy served as Chief Medical Officer and President of product development at Verily, Alphabet's precision health business, overseeing efforts to better connect clinical research and care. Prior to that, she was the first chief medical officer and chief scientific officer at Flatiron Health, and held key academic roles at Duke University, including; professor of medicine at Duke University School of Medicine, director of the Center for Learning Health Care at the Duke Clinical Research Institute, and, director of the Duke Cancer Care Research Program at the Duke Cancer Institute. Trained as a hematologist/oncologist and palliative medicine physician, Dr. Abernethy is also an active scholar with more than 500 publications and remains a committed learner and teacher, dedicated to making healthcare work better for all.

Samir Khleif, MD (Co-Chair)
Georgetown University Medical Center

Dr. Samir Khleif is an immunologist and immune therapist. His research program is "translational tumor immunology" focused on understanding mechanisms through which the immune system and cancer cells interact and how to overcome tumor tolerance in developing therapeutic approaches. Specifically, his research interests include developing novel immune therapeutics, cancer vaccines and delineating the mechanisms of resistance to immunotherapy. Prior to transferring his research program to Georgetown University in 2017, Dr. Khelif served as the Director of Georgia Cancer Center, Augusta University. As Director of the Georgia Cancer Center, Dr. Khleif oversaw the development of a large integrated program of basic scientists and clinicians merging the Cancer Center strength in immunology, inflammation and tolerance basic science and immune therapy.

Dr. Khleif was an intramural NIH scientist for about 20 years. While at NCI, he also served as a leader of the Cancer Vaccine Section, leading a nationally active Immune Therapy Program. His laboratory has conducted some of the earliest clinical trials in antigen vaccines and was the first to conduct vaccines against mutant oncogenes. Also, in the past few years some of the discoveries made in his laboratory have been translated into first-in-human immune therapy clinical trials. Furthermore, Dr. Khleif has published several studies on the mechanisms of tumor-induced suppression in animal models and has overcome such inhibition by developing strategies that have been translated into clinical trials. His laboratory has developed models to understand how different kinds of immune therapies can be combined to work synergistically and translated into clinical trials.

Crystal Denlinger, MD, FACP
National Comprehensive Cancer Network

Dr. Crystal Denlinger is the Chief Executive Officer at the National Comprehensive Cancer Network (NCCN). Dr. Denlinger became CEO in October 2023 after serving as NCCN's Senior Vice President, Chief Scientific Officer.

Dr. Denlinger has a long history of global cancer care leadership with NCCN and beyond. She was named an NCCN Young Investigator Awardee in 2012 and received the NCCN Rodger Winn Award in 2018 for exemplifying leadership, drive, and commitment in service to developing NCCN Clinical Practice Guidelines in Oncology. Before being named Chief Scientific Officer in January 2021, she was chair of the NCCN Guidelines Panel for Survivorship, as well as serving on the Bone, Esophageal/Gastric, and Occult Primary Cancers Panel, the Panel for Older Adult Oncology, the JNCCN-Journal of the National Comprehensive Cancer Network Editorial Board, numerous abstract and scientific review committees, and participated in NCCN's work on NCCN Harmonized Guidelines for Sub-Saharan Africa.

Prior to joining NCCN, Dr. Denlinger served as Chief, Gastrointestinal Medical Oncology; Deputy Director, Early Drug Development Phase 1 Program; Director Survivorship Program; and Associate Professor, Department of Hematology/Oncology at Fox Chase Cancer Center, an NCCN Member Institution.

Dr. Denlinger graduated from a combined BS/MD program at The College of New Jersey and Rutgers New Jersey Medical School, followed by an internal medicine residency with Mount Sinai Medical Center, and hematology/oncology fellowship at Fox Chase Cancer Center/Temple University Hospital. She has authored hundreds of clinical research articles and abstracts and received numerous awards from organizations that include the American Society of Clinical Oncology and the American College of Physicians.

Usama M. Fayyad, PhD
Northeastern University; Open Insights

Dr. Usama M. Fayyad is Chairman of Open Insights, an AI and Data technology and consulting firm he founded in 2008 after leaving Yahoo! to help enterprises deploy Data-driven solutions to grow revenue from AI and data assets. He is also SVP for AI & Data Strategy, Sr. Advisor to the President, and the Inaugural Director of the Institute for Experiential AI at Northeastern University where he is a professor of the practice at Khoury College of Computer Sciences. Dr. Fayyad became the first person to hold the Chief Data Officer title when Yahoo! acquired his second startup after leaving Microsoft. As Yahoo!'s CDO & EVP of Strategic Data Solutions he also founded and led Yahoo Research Labs to become one the of the top research institutions focused on the sciences underlying the Internet.

Dr. Fayyad's previous roles include Global Chief Data Officer at Barclays Bank where he also took on the role of CIO of Finance, Risk, & Treasury Technology. He is Founding Executive Chairman at Oasis500 and an early stage technology accelerator in the Middle East. He served as co-founder & CTO of OODA Health, held leadership roles at Microsoft and founded the Machine Learning Systems group at NASA's Jet Propulsion Laboratory, where his work on machine learning garnered him the top Excellence in Research award from Caltech and a U.S. Government medal from NASA.

Dr. Fayyad earned his Ph.D. in engineering in AI/Machine Learning from the University of Michigan, Ann Arbor and holds two Bachelor of Science in Engineering degrees in EE and CE, MSE Computer Engineering and M.Sc. in Mathematics. Fayyad has published over 100 technical articles on data mining, data science, AI/ML, and databases. He holds over 20 patents and is a Fellow of both the Association for the Advancement of Artificial Intelligence (AAAI) and the Association for Computing Machinery (ACM). He has edited two influential books on data mining/data science and served as Founding Editor-in-Chief on two key journals in the field.

Sarah M. Greene, MPH
Cancer Research Advocate

Ms. Sarah Greene is a consultant, researcher, and cancer survivor with expertise in learning health systems, health communication, electronic health data, and patient-centered care. Much of her career has been focused on building productive, sustainable multi-site networks that conducted applied research on cancer, aging, and communication. She applies a versatile skillset and intellectual curiosity in the areas of digital health, evidence mobilization, and community engagement, and is a recognized national leader in understanding how to bridge research and healthcare delivery using a learning health systems approach. Ms. Greene's perspectives are deeply informed by her recent experience with a cancer diagnosis and successful treatment. Along with a growing portfolio of advocacy work, her recent consulting clients have included the National Academy of Medicine, Trillium Health Partners, the National Cancer Institute, and Kaiser Permanente. Prior to consulting, Ms. Greene was the inaugural Executive Director of the Health Care Systems Research Network, a national consortium of embedded research centers, where she led all of the organization's activities. Ms. Greene also served as an Associate Director at the Patient-Centered Outcomes Research Institute, providing strategic leadership for PCORI's National Patient-Centered Clinical Research Network, PCORnet®. Throughout her career, Ms. Greene has led numerous strategic planning and change management initiatives and complements these skills with strong technical capabilities including literature synthesis, survey design, evaluation, and qualitative analysis. An accomplished writer and speaker with more than 200 publications and presentations, she has shared her work at the National Academy of Medicine, Society for Gynecologic Oncology, American College of Cardiology, American Medical Informatics Association, and AcademyHealth, among other organizations. Ms. Greene received both her MPH and a BA in Psychology and Italian from Indiana University and was recently named a Fellow of the American Medical Informatics Association.

Roy S. Herbst, MD, PhD
Yale University

Dr. Roy S. Herbst is Ensign Professor of Medicine at Yale School of Medicine, Deputy Director for Yale Cancer Center (YCC), Chief of Medical Oncology and Hematology, and Program Director, Master of Health Science—Clinical Investigation track at Yale School of Medicine. He is the principal investigator (PI) of the Yale SPORE in Lung Cancer, PI of the YCC Advanced Training Program for Physician-Scientists, PI on the National Cancer Institute (NCI) NCTN LAPS Grant, and PI of the Yale-AstraZeneca Alliance, which has 12 projects spanning various cancer types.

Dr. Herbst has led Phase I development of multiple targeted agents for non-small cell lung cancer, including gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and anti-PD1/PDL1 therapies. Additionally, he has helped bring targeted therapy to early-stage disease as the PI of the adjuvant osimertinib study (ADAURA). He co-led MD Anderson's lung cancer BATTLE-1 effort, which led to the BATTLE-2 trial defining biomarkers as standard for the use of targeted therapies. He served as the national PI of the SWOG S0819 trial and held the role of founding PI for the NCI Lung Cancer Master Protocol (Lung-MAP, S1400) for a decade. He has authored or coauthored more than 450 publications, and his work published in Nature was awarded Clinical Research Forum's 2015 Herbert Pardes Clinical Research Excellence Award.

Dr. Herbst is a member of the National Cancer Policy Forum for which he organized National Academy of Medicine meetings focused on policy issues in personalized medicine, tobacco control, and public-private partnerships. He is an elected member of the NCI Thoracic Malignancies Steering Committee and the chair of the American Association for Cancer Research Science Policy and Government Affairs Committee. He is a member of the Association of American Physicians. Dr. Herbst received the 2022 Giants of Cancer Care® award for lung cancer and was selected by the Friends of Cancer Research as one of their 25 scientific and advocacy leaders who have been instrumental over the last 25 years in making significant advancements for patients. Most recently, Dr. Herbst received the 2024 Ezra Greenspan Award from the Chemotherapy+ Foundation for the work he has done throughout his career and the work he continues to do for lung cancer patients.

Hedvig Hricak, MD, PhD, Drhc[m]
Memorial Sloan Kettering Cancer Center

Dr. Hedvig Hricak is Emeritus Chair of Radiology at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a leading figure in the field of radiology. She served as Chair of the Department of Radiology at MSKCC from 1999 to early 2023 and, until she transitioned to an emeritus position in August 2025, was a member of the Molecular Pharmacology Program at the Sloan Kettering Institute, and a Professor at the Gerstner Sloan Kettering Institute of Biomedical Sciences. She is an Emeritus Professor of Radiology at Weill Cornell College of Medicine, New York, NY.

The hallmark of Dr. Hricak research career has been the development, validation, and dissemination of new diagnostic imaging techniques, particularly for oncology; she is actively engaged in developing evidence-based imaging guidelines and introducing the concept of integrated diagnostics for oncology. She is actively engaged in global health initiatives that promote international education and collaboration to enhance the quality and accessibility of oncologic imaging and cancer care. She recently co-chaired the steering committee that facilitated the passage of the 78th World Health Assembly (WHA) Resolution on Strengthening Medical Imaging Capacity.

Dr. Hricak's research accomplishments and her efforts to promote national and international education and collaboration in oncologic imaging have won her numerous awards, including the David Rall Medal for Distinguished Leadership from the National Academy of Medicine, nine gold medals, and honorary fellowships or memberships in twenty-two international radiological societies. She holds honorary doctorates from Ludwig-Maximilians-Universität München and the University of Toulouse III (Paul Sabatier), Toulouse, France. Dr. Hricak is a member of the National Academy of and a "foreign" member of both the Russian Academy of Sciences and the Croatian Academy of Sciences and Arts. She has served on several national advisory boards and councils, including the National Institutes of Health Board of Scientific Counselors, the Scientific Advisory Board of the National Cancer Institute, the Advisory Council of the National Institute of Biomedical Imaging and Bioengineering, and the Nuclear and Radiation Studies Board, National Academy of Sciences. Dr. Hricak has also served as chair, co-chair, or member of several Institute of Medicine/National Academy of Medicine and National Academy of Sciences studies.

Chanita Hughes Halbert, PhD
University of Southern California

The goal of Dr. Chanita Hughes Halbert's research program is to improve the precision of multilevel strategies for achieving health equity by identifying diverse determinants of minority health and cancer health disparities and by translating this information into sustainable interventions in clinic and community-based settings to improve cancer outcomes and chronic disease management in disparity populations in local and regional geographic areas.

Dr. Hughes Halbert is a nationally recognized expert in cancer prevention and control among diverse populations and her research is supported by numerous grants from the National Cancer Institute, the National Institutes on Minority Health and Health Disparities, and the Veteran's Affairs Medicine Center. Previously, she was a member of the Board of Scientific Advisors at the National Cancer Institute and the National Human Genome Research Institute Advisory Council. Dr. Hughes Halbert is a past recipient of the AACR Distinguished Lecture in Cancer Health Disparities Award and is a member of the National Academy of Medicine.



Beth Karlan, MD
David Geffen School of Medicine at UCLA

Dr. Beth Y. Karlan is Professor and Vice Chair in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA. She holds the Nancy Marks endowed chair in Women's Health Research and is the Director of Cancer Population Genetics at the UCLA Jonsson Comprehensive Cancer Center. Dr. Karlan's research focuses on improving outcomes for women with ovarian and other gynecologic malignancies as well as better characterizing inherited cancer susceptibility syndromes. She has authored over 500 peer-reviewed research publications. For more than ten years she was Editor-in-Chief of the journals *Gynecologic Oncology* and *Gynecologic Oncology Reports* and now serves as Editor Emeritus of both journals.

Dr. Karlan is an American Cancer Society Clinical Research Professor and has served in many national leadership roles including president of the Society of Gynecologic Oncology. She has helped train a generation of physicians and scientists who are making their own contributions to medicine. Dr. Karlan served on the National Cancer Advisory Board and is a member of the National Academy of Medicine and the National Cancer Policy Forum. Her contributions have been recognized by her peers with multiple awards including a Lifetime Achievement Award from the International Society of Gynecologic Cancer, a Director's Service Award from the National Cancer Institute and a Giant of Cancer Care in Gynecologic Malignancies from OncLive.

Cleo A. Ryals, PhD
Flatiron Health

Dr. Cleo A. Ryals is the Head of Health Equity Research at Flatiron Health, where she is tasked with developing and executing Flatiron's company-wide health equity strategy with the goal of advancing cancer health equity through real-world evidence generation. Dr. Ryals is a health services researcher by training with expertise in cancer health equity, real-world data and evidence generation, health equity research methodology and data analytics, clinical trial diversity, and community engagement. She is a nationally recognized and highly sought after health equity researcher and leader with several publications on topics related to health equity and oncology care.

Prior to joining Flatiron Health, Dr. Ryals was a tenured Associate Professor of Health Policy and Management at the UNC Chapel Gillings School of Global Public Health, where she built substantial health equity research and training programs and was the Founding Director of the Centering Racial Equity in Data Science (CREDS) Initiative at the UNC Lineberger Comprehensive Cancer Center. Dr. Ryals has also held positions within multiple federal offices/agencies, including the former United States Senate Office of Barack Obama, the Office of the National Coordinator for Health Information Technology, and the Government Accountability Office. In 2019, Dr. Ryals was recognized as a '40 Under 40' Leader in Minority Health by the National Minority Quality Forum and Congressional Black Caucus. Dr. Ryals holds a PhD in Health Policy from Harvard University.

Lawrence N. Shulman, MD, MACP, FASCO
University of Pennsylvania

Dr. Lawrence N. Shulman is Professor of Medicine at the Perelman School of Medicine, the Associate Director for Special Projects at the Abramson Cancer Center at the University of Pennsylvania, and Co-Director of the Center for Global Oncology. He received his MD from Harvard Medical School and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Dr. Shulman is the Past-Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer's Quality Integration Committee. A specialist in the treatment of patients with breast cancer, his research includes development of new cancer therapies, and implementation of cancer treatment programs in low-resource settings.

In this regard, Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda, Lesotho, and Haiti, programs for which he plays a seminal leadership role.

Amye Tevaarwerk, MD
Mayo Clinic

Dr. Amye Tevaarwerk is currently the Practice Chair and Professor of Oncology for the Division of Oncology at the Mayo Clinic in Rochester, MN. She is Vice-Chair of the NCCN EHR Advisory Group and the Director of Clinical Informatics for the Alliance and a long-standing member of the Epic Oncology Steering Board.

Dr. Tevaarwerk is board-certified in Oncology and Clinical Informatics, as well as being an Epic-certified Physician Builder. Her clinical practice specializes in breast cancer. Her research interests include leveraging electronic health records and other healthcare information technology tools to facilitate communication and care coordination between cancer specialists, primary care and survivors, as well as employment changes related to cancer diagnosis. She has been funded by NIDDLR and NIH.

Dr. Tevaarwerk completed residency at Barnes-Jewish in 2005 followed by a medical oncology fellowship at the University of Wisconsin (UW). She joined the UW faculty in 2008 as an Assistant Professor and became an Associate Professor in 2016, with a clinical practice specializing in breast cancer. In 2022, she transitioned from the UW to Mayo Clinic in Rochester, Minnesota.

Robert A. Winn, MD
Massey Comprehensive Cancer Center, Virginia Commonwealth University

Dr. Robert A. Winn is the Director of Virginia Commonwealth University Massey Comprehensive Cancer Center. His current basic science research focuses on the translational aspects of the role that proliferation pathways and cellular senescence play in lung cancer. Dr. Winn has also brought the importance of the concept of ZNA (i.e., one's zip code or neighborhood of association) and its impact on DNA and biological outcomes to the forefront in basic and translational research.

Dr. Winn is a principal investigator on several community-oriented projects funded by the NIH and National Cancer Institute. Winn is the Immediate Past President of the Association of American Cancer Institutes (AACI); Chair of the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine; and a member of the Board of Directors for the American Cancer Society and LUNGevity Foundation. Dr. Winn holds a BA from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Speaker Biosketches

Emily Boja, PhD
Office of Data Sharing
National Cancer Institute

Dr. Emily Boja is Branch Chief in the Office of Data Sharing at the National Cancer Institute (NCI), where she leads implementation of the NIH data sharing policies, e.g., Data Management and Sharing and Genomic Data Sharing policies. She serves as the Co-Chair of the NCI and Gabriella Miller Kids First (GMKF) Data Access Committees. In this role, she provides strategic and programmatic leadership to advance broad and responsible data sharing, strengthen governance and implement streamlined processes for controlled-access data, and accelerate data use and reuse across the cancer research community. She supports development and integration of complementary multi-omics data generation pipelines for the Childhood Cancer Data Initiative (CCDI)'s Molecular Characterization Initiative and GMKF proteogenomics projects, as well as promotes interdisciplinary collaborations to enhance data utility through data jamborees, workshops, and collaborative efforts.

With more than 26 years of service across the U.S. Department of Health and Human Services, including positions at NIH and the FDA, Dr. Boja has led major proteogenomics and data-driven research programs. Her leadership includes NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the International Cancer Proteogenome Consortium, as well as the precisionFDA crowdsourced community engagement program.

Dr. Boja has authored over 80 peer-reviewed publications and earned her Ph.D. in Biochemistry and Molecular Biology from the Medical College of Virginia at Virginia Commonwealth University.

Daniel Chu, MBA, MPA
23andMe Research Institute

Mr. Dan Chu serves as the Chief Product Officer at the 23andMe Research Institute, a nonprofit medical research organization that enables people everywhere to access their genetic information, learn about themselves, and participate in the world's largest crowdsourced research initiative. His work focuses on developing consumer health services, including launching 23andMe's Total Health membership, which provides clinical-grade exome sequencing, telehealth consultations, and comprehensive blood testing.

Previously, Mr. Chu was the Chief Product Officer for Waymo, where he helped take autonomous driving from science fiction to commercial reality, overseeing the launch of the world's first fully autonomous ride-hailing service. Before Waymo, he led the Google Maps platform product team, managing the Google Maps API, one of the most popular APIs in the world.

Mr. Chu holds a B.S. in Computer Science and an A.B. in Economics from Stanford University, an MBA from Harvard Business School, and an MPA from the Harvard Kennedy School.

Caroline Chung, MD, MSc
MD Anderson Cancer Center

Dr. Caroline Chung is Vice President, Chief Data & Analytics Officer, and Co-Director of the Institute for Data Science in Oncology at MD Anderson Cancer Center. She is a tenured professor in Radiation Oncology and Diagnostic Imaging with a clinical practice focused on CNS malignancies and a computational imaging lab focused on quantitative imaging and modeling to detect and characterize tumors and toxicities of treatment to enable personalized cancer treatment. Motivated by challenges observed in her own clinical and research pursuits, Dr. Chung has developed and leads institutional efforts to enable quantitative measurements for clinically impactful utilization and interpretation of data through a collaborative team science approach, including the Tumor Measurement Initiative (TMI) at MD Anderson.

Internationally, Dr. Chung leads multidisciplinary efforts to drive high quality, quantitative data with data science for precision medicine research and clinical practice, including her role as Co-Chair of the Quantitative Imaging for Assessment of Response in Oncology Committee of the International Commission on Radiation Units and Measurements (ICRU) and co-president of the Quantitative Medical Imaging Coalition (QMIC) and co-chair of the American Society of Clinical Oncology (ASCO) AI Community of Practice. She served as a member of the National Academies of Sciences, Engineering, and Medicine (NASEM)-appointed committee addressing Foundational Research Gaps and Future Directions for Digital Twins. She is also chair of a non-profit organization focused on fostering leadership, mentorship and sponsorship to support the broad community and team needed to advance cancer treatment and care called Women in Cancer-All in Cancer.

Aaron Cohen, MD, MSCE
Flatiron Health; NYU Grossman School of Medicine

Dr. Aaron Cohen is the Senior Medical Director and Clinical Lead of AI and Digital Oncology at Flatiron Health. An oncologist and informatician, Dr. Cohen drives AI-enabled oncology innovation by accelerating advances in predictive modeling and shaping the strategic direction of novel AI-powered solutions, services, and tools across Flatiron. He is a leading voice in ensuring that AI applications, including Large Language Models (LLMs), are clinically meaningful, safe, and of sufficient quality to enable actionable research. Much of this work, spanning LLM-extracted data curation, predictive modeling, and outcomes research, is conducted in collaboration with groups such as the FDA, the Duke-Margolis Institute, and the GetReal Institute, as well as leading academic institutions, and has been published extensively at the intersection of technology and oncology.

Beyond his role at Flatiron, Dr. Cohen is a practicing oncologist and Adjunct Assistant Professor at the NYU School of Medicine, where he treats patients with solid tumor malignancies at Bellevue Hospital. He completed his MD and MS in Clinical Epidemiology at the University of Pennsylvania, where he also completed his residency and fellowship training. Dr. Cohen is triple-board certified in Internal Medicine, Medical Oncology, and Clinical Informatics.

Shannon M. Dean, MD, MMM
St. Jude Children's Research Hospital

Dr. Shannon M. Dean currently serves as Vice President and Chief Medical Information Officer at St. Jude Children's Research Hospital. She is a member in the Department of Pediatrics at St. Jude and practices clinically as a pediatric hospitalist. Prior to joining St. Jude in August 2021, Dr. Dean served as Professor of Pediatrics in the Department of Pediatrics, Division of Hospital Medicine for the University of Wisconsin School of Medicine and Public Health and as the inaugural CMIO for UW Health from 2014-2021. She earned her Doctor of Medicine degree from the University of Wisconsin School of Medicine in 2002. Dr. Dean was a pediatric resident from 2002 to 2005 and a fellow in Pediatric Hematology/Oncology from 2005 to 2007, both in the Department of Pediatrics at the University of Wisconsin Hospital and Clinics in Madison.

Dr. Dean's ongoing commitment to learning and leadership training led to achieving her board certification in clinical informatics in 2017, and she completed her Master of Medical Management degree from Carnegie Mellon University in 2021. Dr. Dean's academic contributions include publications in the areas of technology to improve patient engagement and patient safety and optimizations to documentation in the EHR. She has mentored many investigators on optimal use of the EHR to support research. She currently serves as Vice Chair for Epic's Children's Health Leadership Council.

Hamid Emamekhoo, MD, FAMIA
University of Wisconsin Carbone Cancer Center

Dr. Hamid Emamekhoo is an Associate Professor of Medicine (Hematology/Oncology) at the University of Wisconsin–Madison and serves as Medical Director of Clinical Cancer Research Informatics at the UW Carbone Cancer Center. He is dual board-certified in Medical Oncology and Clinical Informatics and specializes in genitourinary malignancies.

Dr. Emamekhoo's work focuses on the responsible integration of digital health, artificial intelligence, and structured data capture into oncology care and clinical research. He leads institutional and multi-site initiatives to improve point-of-care data quality, EHR-embedded clinical trial workflows, and AI-enabled tools for patient-centered communication and research-grade real-world data. He is a Co-Principal Investigator at the University of Wisconsin–Madison and co-leader of the Epic EHR Build Workgroup for the NCI-funded EHR Pilot Consortium (EPC), focused on the scalable deployment of centrally built, standardized EHR-based clinical trial treatment plans.

Nationally, Dr. Emamekhoo serves in leadership roles with Epic's Oncology Specialty Steering Board, NCCN's EHR Advisory Group, and ASCO informatics and guideline initiatives. He has authored over 40 peer-reviewed publications spanning oncology, informatics, and health services research, and regularly advises on governance, validation, and implementation considerations for AI in cancer care.

Jennifer Goldsack, MChem, MA, MBA, OLY
Digital Medicine Society (DiMe)

Jennifer C. Goldsack is the founder and CEO of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit dedicated to advancing digital medicine to optimize human health. Her work focuses on practical approaches to the safe, effective, and equitable use of digital technologies to improve health, healthcare, and health research.

Jennifer also brings the perspective of a patient navigating late-stage cancer, adding urgency and authenticity to her commitment to reshaping health care. She is a retired elite athlete – a Pan American Games champion, Olympian, and former world record holder.

Jennifer serves on the board of Sage Bionetworks, is a member of the National Academies of Sciences, Engineering, and Medicine's Roundtable on Genomics and Precision Health, contributes to the World Economic Forum's Digital Health Action Collaborative, and is an Executive Committee Member of the U.S. Department of Health and Human Services' National Committee on Vital and Health Statistics (NCVHS).

Jennifer earned a master's degree in chemistry from the University of Oxford, a master's in the history and sociology of medicine from the University of Pennsylvania, and an MBA from the George Washington University.

William A. Hall, MD
Medical College of Wisconsin

Dr. Bill Hall is the Chair of the Department of Radiation Oncology at the Medical College of Wisconsin and holds the Bob Uecker endowed chair of pancreatic cancer research. As a practicing radiation oncologist Dr. Hall balances a robust clinical practice along with serving as the national principal investigator on several NCI funded cooperative group trials. Such trials span multiple different malignancies with a particular focus on both GU and GI malignancies. Dr. Hall has published over 125 peer reviewed manuscripts many of which are highly cited as his current H-index is 48, he also currently serves as the M-PI or Co-I of several NIH R-01's, and is the cofounder of a venture capital backed startup company developing a new method of image guidance for radiation delivery.

Dr. Hall's most recent research focus in pancreatic cancer is on understanding the influence of different radiation fractionation schedules on the immune micro environment with an intent to design novel and custom theranostic agents to both precisely treat and image pancreatic cancer.

Michael Hassett, MD, MPH
Dana-Farber Cancer Institute; Harvard Medical School

Dr. Michael Hassett is the Chief Quality Officer at Dana-Farber where he is also a researcher in the Division of Population Sciences and a medical oncologist in the Breast Oncology Center. He is an Associate Professor of Medicine at HMS. He is dedicated to ensuring that all patients receive high quality, patient centered, personalized cancer care. His work focuses on the use of health information technology (e.g., the EHR, patient apps, and AI) and implementation science to address disparities, improve outcomes, and maximize the patient experience.

Prior to joining the faculty at Dana-Farber 23 years ago, Dr. Hassett received his MD from the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, completed his MPH at the Harvard T.H. Chan School of Public Health, served as Resident and Chief Resident in Internal Medicine at the University of Rochester, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute & Mass General Brigham.



Eric Horvitz, MD, PhD
Microsoft Research

Dr. Eric Horvitz is Microsoft's Chief Scientific Officer and Director Emeritus of Microsoft Research. He leads strategic initiatives at the intersection of AI, biosciences, and healthcare. His contributions to AI and human-AI collaboration have been recognized with the Allen Newell and Feigenbaum Prizes, and induction into the CHI Academy. A member of the National Academy of Engineering and the American Academy of Arts and Sciences, he has served as President of AAAI, Commissioner on the National Security Commission on AI, and on the National Academy of Medicine's AI Code of Conduct Steering Committee. He is a Fellow of AAAI, ACM, AAAS, and the American College of Medical Informatics, and served on the Board of Regents of the National Library of Medicine. He received his MD and PhD from Stanford University.



Yulin Hswen, ScD, MPH
University of Maryland

Dr. Yulin Hswen is an Associate Professor at University of Maryland in the Department of Epidemiology and Biostatistics and in the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) within College of Computer mathematical and natural sciences

Dr. Hswen earned her doctorate in social and computational epidemiology from Harvard T.H. Chan School of Public Health. Her research sits at the crossroads of artificial intelligence, digital data science, and public health. She studies how information and narratives spread through social media and online networks, and how these digital flows shape population behaviors, beliefs, and health outcomes.

In particular Dr. Hswen developed a framework called AI Y Checklist for Population Ethics, which provides structured ethical guidelines for evaluating AI tools used in public health and population-level interventions. This framework highlights core principles such as model generalizability, contextual adaptability, transparency, and accountability when deploying AI in diverse global settings.

Dr. Hswen is also Associate Editor at *JAMA* and host of the *JAMA+ AI* Conversations podcast, where she interviews leading scientists and clinicians on cutting edge advances in artificial intelligence and medicine. She also curates JAMAAI.org, organizing and accelerating AI research across the entire JAMA Network to make emerging evidence accessible for clinical, scientific, and policy audiences.

Praduman Jain, MS
Vibrent Health

Mr. Praduman Jain (PJ) is the founder and CEO of Vibrent Health and also principal investigator of several large government, academic and industry programs including the NIH All of Us Program, NCI, ARPA-H to build genomics and data platforms for biomedical and clinical research and trials. Under Jain's leadership, the government awarded Vibrent $160 million over many years to build and manage a national platform for clinical research for one million people across the U.S.

Mr. Jain brings deep expertise in digital health architectures, secure cloud hosted backends, mobile apps and APIs for large scale and robust implementation to collect, harmonize and share multi-mode data from genomics, EHRs, SDoH, surveys, ePROs, wearables, eCRFs, medication adherence, more. He is passionate about advancing health equity by creating solutions that enhance cancer care and research.

Mr. Jain collaborates with Cancer Centers, NCI and life sciences companies to build next-generation, patient-centered, collaborative clinical research data-management infrastructures. Mr. Jain advises the industry about trends in clinical research and steps they can take to advance science and stay competitive. Mr. Jain holds 120+ issued US patents, M.S., B.S. degrees in Electrical Engineering and has published extensively in peer-reviewed scientific journals.

Brian A. Jones BCPA, CCHW
Zero Prostate Health Equity Taskforce

Mr. Brian Jones is a 10-year prostate cancer survivor, patient and advocate who resides in Harrisburg, PA. The majority of Mr. Jones professional experience has been in the pharmacy space where he severed in many roles including 15 years as the Fulfillment Services Manager. Currently he is employed with Temple University Harrisburg where he serves as an adjunct professor and Subject Matter Expert (SME).

Since recovering from cancer surgery in 2016 Mr. Jones has dedicated his life to an ongoing cycle of learning more about prostate cancer and being an advocate for cancer patients across the globe. One of the many highlights in Mr. Jones' career was being a co-author on a published

paper Assessing barriers to prostate cancer clinical trial participation among Blacks and African Americans: A multi-perspective qualitative study. Mr. Jones is a Certified Community Health Worker, Board Certified Patient Advocate (BCPA), a member of the following organizations, Zero Prostate Health Equity Taskforce, the Patient Engagement Advisory Panel with the Patient Centered Outcomes Research Institute (PCORI) and a Board Member with the Pennsylvania Prostate Cancer Coalition (PPCC).

Mr. Jones is a loving husband, father, coach and community leader. In his spare time, he enjoys travelling around the world with his family, reading, participating in 5k & 10k races, cooking and attending college basketball games. The motto that he lives by is "Advocating for those who can't while supporting those who can".



Jakob Nikolas Kather, MD, MSc
TUD Dresden University of Technology

Professor Jakob Kather holds dual appointments in medicine and computer science at the Dresden University of Technology, Germany, serves as a senior physician in medical oncology at the University Hospital Dresden and holds an additional affiliation with the National Center for Tumor Diseases (NCT) in Heidelberg. His research is focused on applying artificial intelligence in precision oncology. Prof. Kather's research team at TU Dresden is using deep learning techniques to analyze a spectrum of clinical data, including histopathology, radiology images, textual records, and multimodal datasets. Guided by the belief that medical and tech expertise needs to be combined, medical researchers in his team learn computer programming and data analysis, while computer scientists are immersed in cancer biology and oncology.

Prof. Kather chairs the "Working group on Artificial Intelligence" at the German Society of Hematology and Oncology (DGHO) and is a member of the pathology task force of the American Association for Cancer Research (AACR). His work is supported by numerous European and national grants, which enable the team to develop new deep learning methods for medical data analysis techniques and to apply them in precision oncology.

Fabio Y. Moraes, MD, PhD, MBA
Queen's University

Dr. Fabio Ynoe de Moraes is an Associate Professor of Radiation Oncology at Queen's University and a Clinician-Scientist at the Sinclair Cancer Research Institute. A globally recognized leader at the nexus of oncology, health policy, and artificial intelligence, he directs an innovative research program dedicated to advancing equitable cancer care through evidence-based technology implementation, health systems strengthening, and international collaboration.

Since joining Queen's University in 2019, Dr. Moraes has uniquely bridged clinical practice, scientific discovery, and health system leadership—completing a PhD in Health Sciences, an MBA, and advanced training in Artificial Intelligence in Health. An exceptionally prolific scholar, he has authored over 190 peer-reviewed publications in premier journals including *The New England Journal of Medicine, JAMA Oncology, The Lancet Oncology*, and *Nature*. He holds leadership roles in global oncology initiatives and institutional innovation strategy, championing scalable solutions that address disparities in cancer outcomes across high- and low-resource health systems.

Dr. Moraes' mission centers on ensuring that technological advances, from AI-driven diagnostics to precision radiation oncology, translate into accessible, just, and effective care for all patients, regardless of geography or socioeconomic context.

Wilfred Ngwa, PhD
U.S. Advanced Research Projects Agency for Health (ARPA-H)

Prof. Wil Ngwa is a Program Manager leading the development of the "Comprehensive Cancer Center in the Cloud powered by AI" platform and other programs with the U.S. governments Advanced Research Projects Agency for Health. He has served as Advisor to the White House office of Science and Technology Policy on cancer. He is Founding Director/PI of the Global Health Catalyst at Harvard and Johns Hopkins with pioneering initiatives including the development of "Tiny Drones to Target Cancer" at Brigham and Women's Hospital Harvard Medical School, and the Global Oncology University training the workforce of the future leveraging advanced Information and Communication Technology and AI. He has held faculty appointments as ICTU Distinguished Professor of Public Health, Rutgers Presidential Faculty Professor of Global Health and Radiation Oncology and visiting professorships at the University of Pennsylvania and University of Heidelberg Germany.

Prof. Ngwa has won over 45 prestigious awards/honors at Harvard, Johns Hopkins, international professional societies and organizations including the U.S. President's Life-Time Achievement Award. He completed his studies in Physics and computer science at University of Buea and University of Leipzig Germany, and clinical training in the departments of radiation oncology at MD Anderson Cancer Center and Harvard Medical School USA.



Shantanu Nundy, MD
Advisor on AI (Contractor)
Office of the Food and Drug Administration Commissioner

Dr. Shantanu Nundy is a serial innovator, practicing physician, and advisor on artificial intelligence to FDA in the Commissioner's Office.

Dr. Nundy has spent the past twenty years bringing innovative tools and emerging technologies to drug development, clinical practice, and public health. He pioneered the use of collective intelligence (humans + AI) in medicine and served as Chief Health Officer at Accolade, an AI-enabled navigation platform serving over 10 million Americans.

Dr. Nundy is the author of two acclaimed books, Stay Healthy At Every Age and Care After Covid, and practices primary care part-time in the safety net. He holds a BS from MIT, MD from The Johns Hopkins University School of Medicine, and MBA from the University of Chicago.

Travis Osterman, DO, MS, FAMIA, FASCO
Vanderbilt University Medical Center

Dr. Travis Osterman is a practicing medical oncologist, informatician, Clinical Director in the Office of the Chief Health Information Officer at Vanderbilt University Medical Center (VUMC), and Director of Cancer Clinical Informatics in the Vanderbilt-Ingram Cancer Center. He is board certified in internal medicine, medical oncology, and clinical informatics and completed a master of science in biomedical informatics at Vanderbilt University. He has dual faculty appointments at VUMC in the Department of Biomedical Informatics and the Department of Medicine in the Division of Hematology and Oncology.

Dr. Osterman's clinical interest within oncology is lung cancer. He leads the Clinical Cancer Informatics Innovation (C2I2) group whose research focuses on applying clinical informatics methods across the cancer care continuum. Current projects include identifying patients for lung cancer screening, automated clinical trial matching, and using predictive analytics to anticipate toxicity to immunotherapy. As part of this work their team develops tools used for both research and to directly support patient care.

Nationally, Dr. Osterman is involved several national efforts to improve the availability of oncology-specific EHR data to support quality improvement across oncology practices. Dr. Osterman serves on the National Comprehensive Cancer

Network (NCCN) Electronic Health Record (EHR) workgroup and Patient Reported Outcomes (PRO) workgroup. The focus of these workgroups includes leveraging the EHR to promote innovation and to standardize best practices across cancer centers. He serves on the American Society of Clinical Oncology (ASCO) CancerLinQ Physician Advisory Board, the Minimum Common Oncology Data Elements (mCODE) workgroup, and the Member and Meeting Publications Editorial Board. Dr. Osterman also represents VUMC as a founding member on the Oncology Clinical Trial Information Commons (OCTIC) project which focuses on standardizing how data describing clinical trials are stored. He also serves on the Epic Adult Oncology Steering Board and chairs Epic's Beacon Community Operations Group.

Etta D. Pisano, MD, FACR, FSBI
American College of Radiology

Dr. Etta Pisano serves as the Chief Research Officer at the American College of Radiology and as the Principal Investigator for the NCI-funded ECOG-ACRIN-sponsored Tomosynthesis Mammographic Imaging Screening Trial (TMIST) which is comparing digital mammography to tomosynthesis for breast cancer screening, which has recruited 108,904 women at 134 sites in the US, Canada, Argentina, Peru, Italy, Spain, Thailand, Taiwan and South Korea since it opened in July 2017.

Dr. Pisano is a member of the National Academy of Medicine and holds faculty appointments in radiology at the University of Pennsylvania and the University of North Carolina at Chapel Hill. Her career has focused on breast imaging with a special emphasis on the development and testing of new technologies, most recently including the application of Artificial Intelligence and Machine Learning to the field of medical imaging.

Fernanda C. G. Polubriaginof, MD, PhD, FAMIA
Memorial Sloan Kettering Cancer Center

Dr. Fernanda Polubriaginof is a healthcare technology leader with deep expertise in clinical informatics, analytics, digital product management, and digital health innovation. She directs population health, value measurement, and clinical analytics efforts that are foundational to enabling a modern learning health system. She leads enterprise initiatives that advance quality and safety, enhance the patient experience, and expand hybrid care models leveraging analytics and technology to improve access, outcomes, and research capabilities.

As a physician-scientist, Dr. Polubriaginof serves as a co-investigator on large federal grants exploring the role of digital health in transforming care. She has authored more than 50 peer-reviewed publications, including work published in Cell, and is recognized for translating complex research and data-driven insights into scalable, real-world solutions that create organizational value and meaningfully improve patient care.

Diana E. Ramos, MD, MPH, MBA
California Surgeon General

Dr. Diana E. Ramos is a distinguished public health leader dedicated to advancing the health and well-being of all communities. As California's Doctor, she is the leading spokesperson on the most pressing public health issues of the time within the State of California. With a steadfast commitment to addressing Adverse Childhood Experiences, mental health, and maternal mortality and morbidity, Dr. Ramos has been a driving force in shaping policies and programs that make a lasting impact. Her mission is simple: to advance the health and wellbeing of all Californians.

Before her historic appointment as California's first Latina Surgeon General, Dr. Ramos served as the Assistant Deputy Director of Chronic Disease Prevention at the California Department of Public Health, spearheading statewide initiatives to improve community health. Her leadership has extended across local, state, and national platforms, from serving as Director for Reproductive Health in Los Angeles County to holding key positions with the American College of Obstetricians and Gynecologists, the American Medical Association Foundation, Women's

Preventive Service Initiative, and the National Hispanic Medical Association.

Over the past three decades, Dr. Ramos has provided compassionate, high-quality reproductive care to thousands of Californians as an Obstetrician Gynecologist at Southern California Kaiser Permanente. Beyond clinical care, she is a prolific contributor to medical and public health literature and a sought-after speaker, delivering lectures in both English and Spanish on local, national, and international stages.

Dr. Ramos' academic achievements are equally impressive. She earned her medical degree from the Keck School of Medicine at USC and serves as an adjunct Associate Professor. She completed her residency in Obstetrics and Gynecology at Los Angeles County-USC Medical Center. She further enhanced her expertise with a Master of Public Health from UCLA and a Master of Business Administration from UC Irvine's Paul Merage School of Business.
In 2024, the California Latino Legislative Caucus awarded Dr. Ramos with the Latino Spirit Ward for Achievement in Public Service and Health.

In 2025, All Children Thrive awarded Dr. Ramos with the Public Health Leadership Award. A visionary leader, an advocate for equity in healthcare, and a champion for vulnerable communities—Dr. Diana E. Ramos is reshaping the future of public health.

Shiv Rao, MD
Abridge

Dr. Shiv Rao is the CEO and Cofounder of Abridge, the leading AI platform for clinical conversations. Abridge's enterprise-grade AI transforms medical conversations into clinically useful and billable documentation at the point of conversation, reducing administrative burden and clinician burnout while improving patient experience. Abridge integrates seamlessly within electronic health record workflows—across care settings, specialties, and spoken languages. In 2025, Abridge was named to the Forbes AI 50 and Cloud 100 lists as well as the Fast Company Most Innovative Companies list. Abridge has also been recognized in the Fortune AI 50 list and as one of *TIME*'s Best Inventions of 2024.

Dr. Rao was also recently named as one of the 100 most influential people in AI by TIME magazine and as one of the 100 Most Influential People in Healthcare by Modern Healthcare. He is a practicing cardiologist at UPMC and previously led the provider-facing investment portfolio for UPMC, where he invested in startups and helped fund a Machine Learning in Health program at Carnegie Mellon University.

Dr. Rao completed his medical education and training at the University of Michigan and the University of Pittsburgh School of Medicine and studied at Carnegie Mellon where he programmed virtual synthesizers and skateboarded in IMAX movies.

Roy Rosin, MBA
First Round Capital

Mr. Roy Rosin is a Board Partner at First Round Capital, a leading early-stage venture capital firm known for supporting industry-defining companies like Uber and Flatiron Health. He works with extraordinary founders who are transforming health care, driving high impact revenue and margin growth for medical practices. Previously, Mr. Rosin served as Chief Innovation Officer at Penn Medicine, rapidly designing, testing, and implementing novel health care interventions to dramatically improve patient outcomes and experience.

Prior to his time in health care, Mr. Rosin served as the first vice president of innovation for Intuit, a leading software company best known for QuickBooks and TurboTax. In this role, he led changes in how Intuit managed business creation, allowing teams to experiment quickly, at low cost. After five years of redesigning entrepreneurial practices, the company delivered shareholder returns 33x the S&P 500. Intuit now consistently appears on Forbes' list of the most innovative companies in the world. Earlier in his career, Mr. Rosin's Quicken team achieved record profitability and product leadership while growing to 14 million consumers.

Mr. Rosin focuses on advising startups and health system leadership teams aiming to make a meaningful difference. He received his MBA from Stanford and graduated with honors from Harvard College.

Nigam H. Shah, MBBS, PhD
Stanford University

Dr. Nigam Shah is Professor of Medicine at Stanford University and serves as the Chief Data Scientist for Stanford Health Care. He is a world-renowned scientist, educator and entrepreneur with deep expertise in the application of machine learning, knowledge representation and artificial intelligence for the analysis of multiple types of health data.

At Stanford Dr. Shah's research develops novel techniques to analyze multiple types of health data – such as electronic health records (EHR), medical claims, wearables, weblogs, and patient blogs – to answer clinical questions, generate insights, and build predictive models for the learning health system. At Stanford Healthcare he oversees responsible use of artificial intelligence for advancing the scientific understanding of disease, improving the practice of clinical medicine and orchestrating the delivery of health care. In 2018, he created the USA's only bedside consultation service that provides a clinician with an on-demand summary of similar patients in terms of the treatment choices made and observed outcomes. This service was cited in congressional testimony by the director of the National Library of Medicine in 2019 and spun out as an independent company in 2020.

Dr. Shah holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University. He joined the Stanford faculty in 2011 and received tenure in 2015, as the fastest and youngest tenured professor at the time. He was elected into the American College of Medical Informatics (ACMI) in 2015, was inducted into the American Society for Clinical Investigation (ASCI) in 2016, and selected into the Stanford Medicine Leadership Academy in 2017. His research has been funded by four NIH institutes, resulted in 350+ publications (h-index 88) including in JAMA, Lancet, Nature Digital Medicine and the New England Journal of Medicine receiving over 38,000 citations and has been covered in the New York Times, Wall Street Journal, Harvard Business Review, and NPR.

Dr. Shah teaches in the Biomedical Informatics (BMI) graduate degree program, and was recognized with the Stanford Faculty Teaching Award for outstanding teaching in 2013. Since 2021, he teaches in the Master of Science in Clinical Informatics Management (MCiM) and launched the AI in Healthcare Specialization on Coursera, reaching over 50,000 students. He serves on the advising faculty of the Clinical Informatics Fellowship at Stanford Medicine.

Dr. Shah is an inventor on nine patents and patent applications, has co-founded three companies that collectively raised over $100M in capital and serves on the Boards of Prealize Health and Atropos Health. He is a member of the National Academy of Medicine's Digital Learning Collaborative and serves as an invited expert for the AI/ML Working group as well as a cofounder of the coalition for health AI, which provides guidelines for the responsible use of AI in healthcare.

Peter D. Stetson, MD, MA, FAMIA
TigerConnect

Dr. Peter Stetson brings decades of experience at the intersection of clinical practice and healthcare technology. Most recently, he served as Chief Health Informatics Officer at Memorial Sloan Kettering in New York, where he oversaw digital health transformation, clinical systems support, and AI adoption efforts. A practicing physician and nationally recognized leader in clinical informatics, Dr. Stetson has built a career helping healthcare organizations leverage technology to improve patient care and operational efficiency.

In addition to his leadership roles, Dr. Stetson is a frequent speaker and advisor on clinical informatics strategy, bringing a unique perspective shaped by both his medical background and his work advancing enterprise-wide technology adoption.

As Chief Medical Information Officer at TigerConnect, Dr. Stetson leads the Clinical Consulting and Solution Design team and strategy. He is passionate about shaping the future of TigerConnect's clinical offerings to meet the evolving needs of healthcare organizations and the patients they serve.



Danny Tobey, MD, JD
DLA Piper Americas AI and Data Analytics Practice

Dr. Danny Tobey is a trusted advisor to the world's most prominent companies, boards, and governments, guiding them through transformative change and complex risk landscapes. With deep experience in emerging technologies, particularly artificial intelligence, Dr. Tobey provides 360-degree support throughout the technology lifecycle, from strategic planning and deployment to governance, optimization, and investigations and/or litigation defense when issues arise. Renowned for his multidisciplinary experience as a seasoned litigator, medical doctor, and successful software founder, Dr. Tobey is recognized by the Financial Times as one of the most "consistently impactful" legal practitioners of the past two decades and "a pioneer in the current shift in the practice of law from reactive to proactive." Clients consistently praise his "creativity, insight, and forward-looking solutions to our most difficult problems," with Chambers USA and Chambers Global describing him as "incredibly impressive and unique" and "on the cutting edge of practitioners." The Library of Congress has honored his writing as the "best of the best in the legal profession."

As a litigator, Dr. Tobey has led clients through their most critical disputes and investigations. He played a pivotal role in securing one of the largest product liability victories in pharmaceutical history, successfully arguing key motions in federal Daubert proceedings. Danny achieved a unanimous reversal in a landmark federal Research & Development (R&D) tax case, dramatically increasing his client's return, and represents a leading cancer charity in enforcing its royalty rights for groundbreaking research. He has also delivered precedent-setting results in emerging technology litigation, including the first successful resolution of a Generative AI hallucination lawsuit for a top global technology company and is leading post-settlement remediation in the first major State Attorney General Generative AI settlement.

Dr. Tobey is a sought-after counselor for companies navigating legal risk in the adoption and development of new technologies, particularly Artificial Intelligence. Chambers Global Spotlight recognizes him as "by far one of the top leaders and industry experts in AI." His thought leadership has been cited by the United Nations for "profound insights on AI, law, and ethics," and by Oxford for his "crucial" innovations in red-teaming AI for legal risk. Dr. Tobey has advised at least half of the Fortune 10, as well as most major hyperscalers and innovators, on their most complex AI challenges.

Leveraging his medical background, Dr. Tobey counsels leading life sciences companies on the most advanced biotechnology issues. Chambers USA highlights his "deep subject matter expertise across technology, law, and healthcare and life sciences." He played a key legal role in the global risk management of the first mRNA Covid vaccine and led risk mitigation for the first fully autonomous Food and Drug Administration (FDA) approved diagnostic device. Dr. Tobey is a frequent presenter on robotics and AI alongside industry leaders such as Johnson & Johnson.

Dr. Tobey leads a hybrid legal and technical team that harnesses AI to proactively manage risk and prevent emerging issues. His team has developed bespoke, client-specific small language models for proactive compliance, enabling early detection of statutory risk, and has rigorously tested AI systems for consumer protection, product liability, discrimination, and other legal exposures. These innovations have earned his firm recognition for Best Law Firm Use of AI (American Lawyer) and Innovation in New Services to Manage Risk (Financial Times), among other accolades.

Deeply committed to community service, Dr. Tobey has chaired the board of the AT&T Performing Arts Center and served on the executive committees of the Perot Museum of Nature & Science, the Parkland Foundation, and the Yale Law School Association. In 2025, he was elected to the American Law Institute. Dr. Tobey is also a co-founder of the United Nations' AI for Good Law Track and the AI Law & Justice Institute, reflecting his dedication to advancing the responsible use of technology in society.

Cheryl Willman, MD
Mayo Clinic Comprehensive Cancer Center

Dr. Cheryl L. Willman is the Stephen and Barbara Slaggie Executive Director, Mayo Clinic Cancer Programs, and Director of the Mayo Clinic Comprehensive Cancer Center across the Mayo Clinic campuses in Minnesota, Arizona, and Florida. Returning in 2021 to join the staff at Mayo Clinic, she is a consultant and professor in the Department of Laboratory Medicine and Pathology and is also recognized with the distinction of the David A. Ahlquist, M.D. Professorship in Cancer Research.

Dr. Willman, an internationally renowned physician-scientist and cancer leader, is a pioneer in the field of cancer genome sciences with a track record of innovation. She has translated her discoveries to new diagnostics, therapeutics, and national clinical trials, resulting in improved patient outcomes. After receiving her medical degree at Mayo Clinic, she completed residency training in pathology at Mayo Clinic and the University of New Mexico (UNM) School of Medicine. Before returning to Mayo Clinic in 2021, she served as Director and CEO of UNM Comprehensive Cancer Center, which she built and developed into one of the nation's National Cancer Institute (NCI)-designated Comprehensive Cancer Centers.

Dr. Willman has been continuously funded for over 35 years by the National Institutes of Health, the NCI, and several cancer foundations. She currently serves as the principal investigator of one of the nation's five NCI-funded Participant Engagement-Cancer Genome Sequencing Centers, focused on discovery of the genomic and environmental causes of cancers in indigenous American Indians in the Southwest. With an H-index of 113 (D-index of 108) and over 400 scientific publications and 60,000 citations, Dr. Willman is ranked as one of the top 500 female scientists in the United States.

Dr. Willman has served in many national leadership roles, including those at the NCI (Board of Scientific Advisors, Board of Scientific Counselors, and the Scientific Advisory Board of the Frederick National Laboratory for Cancer Research) where she has overseen investments in cancer genomics, drug discovery, nanotechnologies, computing and large-scale data analysis, and collaborations with the nation's Department of Energy laboratories. She also has held several national leadership positions in professional organizations, including the American Association of Cancer Research, the American Society of Hematology, and the Leukemia & Lymphoma Society. She was a founder of the field of molecular diagnostic pathology and president of the Association of Molecular Pathologists. She is an elected Fellow of the National Academy of Inventors.

Krishna Yeshwant, MD, MBA
GV (Google Ventures)

Dr. Krishna Yeshwant is a Managing Partner at GV and Co-Lead of the firm's life sciences group. As an investor, he is interested in the entire healthcare spectrum, including care delivery, health IT, devices, diagnostics, payor/provider, and therapeutics. Krishna led GV's early investments in Flatiron Health, Foundation Medicine, Relay Therapeutics, Beam Therapeutics, insitro, One Medical, and Aledade. He also established GV's incubation program, which helped start companies like ROME Therapeutics and Verve Therapeutics.

A Stanford alum, Dr. Yeshwant leveraged his degree in computer science early in his career to help start two successful tech companies: an electronic data interchange company acquired by Hewlett-Packard and a network security company acquired by Symantec. Dr. Yeshwant's path to medicine began in 2002 when he teamed with a group of surgeons at Mass General and Brigham and Women's Hospitals (BWH) in Boston and wrote software to use imaging systems to guide surgical procedures. He went on to graduate from Harvard's MD/MBA program before serving as an attending in internal medicine at BWH. He joined Google in 2008, where he was part of a team that helped in the early days of GV's founding and led the fund's early commitment to investing in life sciences. Dr. Yeshwant is particularly excited by new research that exposes biology more clearly, and he's also working on new approaches to making clinical trials more efficient and ways to bring modern software approaches to healthcare delivery.

National Cancer Policy Forum Staff Biosketches

Sharyl J. Nass, PhD
Senior Program Director
Program on Health Care and Public Health
Center for Health, People, & Places

Dr. Sharyl Nass serves as Senior Program Director for Health Care and Public Health at the National Academies of Sciences, Engineering, and Medicine. The National Academies provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine. The Health Care and Public Health program addresses the delivery of primary and specialty health care across the life course, including care quality and patient safety, workforce, training, and financing, as well as public health services, including prevention, surveillance, epidemiology, and population health improvement. For more than 25 years, Dr. Nass has worked on a broad range of health and science policy topics that include cancer research and care, the quality and safety of health care and clinical trials, developing technologies for precision medicine, and strategies to support clinician and patient well-being. She has a Ph.D. from Georgetown University and undertook postdoctoral training at the Johns Hopkins University School of Medicine, as well as a research fellowship at the Max Planck Institute in Germany. She also holds a B.S. and an M.S. from the University of Wisconsin–Madison. She has been the recipient of the Cecil Medal for Excellence in Health Policy Research, a Distinguished Service Award from the National Academies, the Institute of Medicine staff team achievement award (as team leader), and the Health and Medicine Division Mentor Award.

Francis Kwadwo Amankwah, MPH
Director
National Cancer Policy Forum
Program on Health Care and Public Health
Center for Health, People, & Places

Mr. Francis Amankwah serves as Director of the National Cancer Policy Forum. In 2024, he co-directed the Forum with Dr. Sharyl Nass. For more than 11 years, his work has focused on health disparities, public health, cancer care and research, primary care, drug pricing, and health services research. He has managed numerous consensus study committees, most recently producing the 2024 consensus report *Ending Unequal Treatment: Strategies to Achieve Equitable Health Care and Optimal Health*. He has also contributed to several cancer-related consensus studies, including *Rethinking Race and Ethnicity in Biomedical Research* (2025), *Guiding Cancer Control: A Path to Transformation* (2019), and *Making Medicines Affordable: A National Imperative* (2017). He has also served as responsible staff officer for numerous workshops and convening activities and as rapporteur for several workshop proceedings and proceedings-in-brief. He is a recipient of the Health and Medicine Division Elena Nightingale, Veteran, Mount Everest, and Fineberg staff achievement awards. He is currently pursuing a Ph.D. in Health Services Research at George Mason University. He earned his M.P.H. and a graduate certificate in Global Planning and International Development from Virginia Tech. Raised in Ghana, West Africa, he received his B.S. in Agricultural Science from Kwame Nkrumah University of Science and Technology.

Anna Adler, MPH
Research Associate
Program on Health Care and Public Health
Center for Health, People, & Places

Ms. Anna Adler is a Research Associate for the Program on Health Care and Public Health in the Center for Health, People, and Places at the National Academies of Sciences, Engineering, and Medicine. She currently works on the National Academies consensus study, Assessment of Department of Veterans Affairs Physical and Mental Health Examinations and the Department's Schedule of Rating Disabilities for Disability Compensation Claims Related to Military Sexual Trauma. She started at the Academies in 2023 as the Senior Program Assistant for the National Cancer Policy Forum. She earned her Bachelor of Science in Public Health in May 2023 and her M.P.H in July 2024 from George Washington University. Before joining the Academies, she worked as a research assistant on a project contracted by the CDC Data Modernization Initiative and as an intern with the National Center for Health Research.

Torrie Brown, BA
Program Coordinator
Program on Health Care and Public Health
Center for Health, People, & Places

Ms. Torrie Brown is the Program Coordinator for the Health Care and Public Health program at the National Academies of Sciences, Engineering, and Medicine. She served as both a program coordinator and senior program assistant with the National Academies' former Board on Health Care Services, where she has provided support to projects spanning topics across the health care spectrum. She has a particular interest in health care and public health initiatives at the intersections of disability and rehabilitation. Ms. Brown earned her Bachelor of Arts in anthropology from the University of Maryland, College Park, and has served in various roles within organizations such as the U.S. House of Representatives, Drug Policy Alliance, and Public Citizen.

Makeda (Keda) Haughton, BA
Senior Program Assistant
Program on Health Care and Public Health
Center for Health, People, & Places

Ms. Makeda Haughton serves as a Senior Program Assistant at the National Academies of Sciences, Engineering, and Medicine, where she supports senior leadership and advances high-impact initiatives within the National Cancer Policy Forum. She plays a key role in planning and executing strategic convenings and managing core operational functions. Prior to joining the National Academies, Ms. Haughton built a foundation in corporate marketing and guest engagement at Darden Restaurants, where she supported brand strategy and customer experience initiatives. She also worked in learning and development roles in South Korea, where she designed and implemented programs that strengthened engagement and performance. She holds a Bachelor of Arts in Communication from the University of Central Florida.

NATIONAL ACADEMIES Sciences Engineering Medicine





National Cancer Policy Forum

The National Cancer Policy Forum serves as a trusted venue in which experts can identify emerging high-priority policy issues in cancer research and cancer care and work collaboratively to examine those issues through convening activities focused on opportunities for action. The forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden through prevention and by improving the care and outcomes for those diagnosed with cancer. Forum activities inform the cancer community and the public about critical policy issues through workshops and published reports. The forum has members with a broad range of expertise in cancer, including patient advocates, clinicians, and basic, translational, and clinical scientists. Forum members represent patients, federal agencies, academia, professional organizations, nonprofits, and industry.

The forum has addressed a wide array of topics, including

- enhancing collaborations to accelerate research and development;
- improving the quality and value of care for patients who have been diagnosed with or are at risk for cancer;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence, mortality, and disparities.

NATIONAL CANCER POLICY FORUM

Upcoming and Recent Workshops

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care

Collaborative workshop convened by:
National Cancer Policy Forum
Program on Computing Research, Technologies, and Systems

March 9-10, 2026

The use of artificial intelligence (AI) in healthcare has been growing rapidly in recent years. It is increasingly recognized for its transformative potential in healthcare, particularly in oncology. This workshop will examine the current and potential future uses of AI in cancer care, and discuss ways to anticipate and address challenges related to the integration of these technologies in the care of patients with cancer. With a focus on the responsible and effective use of AI in oncology, the workshop will consider current policy initiatives across health care and the unique needs for oncology care.

Innovative Person-Centered Clinical Cancer Research

September 29-30, 2025

Person-centered clinical research can positively influence the outcomes of clinical research by providing a more accurate representation of real-world patient experiences. It addresses questions that are informed by patient experiences, needs, and perspectives, and involves patients in all stages of research, including design, activation, enrollment, data collection, completion, and outcome reporting. Although patient-reported outcome measures may offer potential benefits for clinical cancer research, challenges in the completeness, reliability, and validity of the data persist. This workshop examined opportunities to overcome these challenges to advance the conduct of innovative, person-centered clinical cancer research to improve outcomes for all patients.

Strategies and Interventions to Strengthen Support for Family Caregiving and to Alleviate Caregiver Burden

Collaborative workshop convened by:
Roundtable on Quality Care for People with Serious Illness
National Cancer Policy Forum
Forum on Aging, Disability, and Independence

June 5-6, 2025

While unpaid, family caregivers can derive significant satisfaction and other positive benefits from caring for a loved one, research reveals that caregivers experience significant physical, psychological, emotional and financial burdens and a decline in their own physical and emotional health as a result of caring for people living with serious illness. This workshop discussed evidence-based interventions and strategies that effectively address the physical, mental, and financial challenges of caregiving.

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care

Collaborative workshop convened by:
National Cancer Policy Forum
Board on Mathematical Sciences and Analytics
Board on Life Sciences

May 20-21, 2025

The concept of cancer engineering involves the application of engineering principles to solve challenges across cancer research and cancer care. This multidisciplinary approach brings together the fields of biology, engineering, and health care to devise innovative solutions that enhance the effectiveness, accessibility, and affordability of cancer care. This workshop considered opportunities to improve patient outcomes through the convergence of engineering with oncology practice, research, and policy.

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Collaborative workshop convened by:
National Cancer Policy Forum
Forum on Mental Health and Substance Use Disorders

March 17-18, 2025

The use of both alcohol and tobacco has independent and synergistic health effects, including links to many different cancers. There is a clear need to better understand the impact of dual use on cancer incidence and outcomes, to improve public education, and to develop oncology clinical practice guidelines for patients who use alcohol and tobacco. This workshop examined the current state of the science and explore strategies to reduce tobacco and alcohol use to lower cancer risk and improve health outcomes.

Examining Clinical Guidelines for the Adoption of Genomic Testing

Collaborative workshop convened by:
Roundtable on Genomics and Precision Health
National Cancer Policy Forum

October 29, 2024

Clinical practice guidelines can impact adoption of new technologies into routine medical care. This workshop examined how guidelines for genomic testing are developed by various organizations, with a focus on exploring inconsistencies across guidelines and opportunities for a possible path forward for more consistent clinical guidelines for genomics to improve patient care.

Recent Workshops

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

October 28-29, 2024

Cancer screening is considered a key cancer control strategy because patients who are diagnosed with earlier stages of disease often have better treatment options and improved health outcomes. However, effective screening tests are lacking for most cancers. The development of minimally invasive approaches to screen for multiple tumor types at once could address this unmet need, but the clinical utility of multicancer detection (MCD) testing has yet to be established.

Enabling 21st Century Applications for Cancer Surveillance Through Enhanced Registries and Beyond

July 29-30, 2024

Population-based cancer surveillance has a pivotal role in assessing the nation's progress in cancer control. Cancer surveillance helps inform research and care interventions aimed at reducing the burden of cancer on patients and communities, including the ability to identify health disparities in cancer outcomes. Surveillance data are crucial for identifying emerging trends in health outcomes and opportunities to improve the quality of cancer care. However, challenges with the current approach to cancer surveillance in the United States include delays and gaps in data collection, as well as inadequate infrastructure and workforce to keep pace with the informatics and treatment-related advances in cancer. The National Cancer Policy Forum convened a public workshop to examine opportunities to enhance and modernize cancer surveillance in order to improve cancer research, care, and outcomes for all patients.

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Collaborative workshop convened by:

Forum on Drug Discovery, Development, and Translation
National Cancer Policy Forum

May 20, 2024

This workshop aimed to explore opportunities to improve racial and ethnic diversity in clinical trials with a focus on system-level change and collective efforts across organizations and sectors that no one entity can effectively take on alone.

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

March 20-21, 2024

Biological effectors of social determinants of health (SDOH) interact and impact cancer risk, treatment outcomes, and health equity. This workshop considered opportunities to advance health equity in cancer by identifying promising avenues for future research, as well as policies and interventions aimed at mitigating the negative impacts of the SDOH in cancer.

Optimizing Public-Private Partnerships for Clinical Cancer Research

Collaborative workshop convened by:

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

October 17-18, 2023

Public-private partnerships (PPPs) have the potential to more effectively leverage public funding and resources, increase the breadth and depth of research, and affect a more rapid translation from basic discoveries to public health applications. Industry, government, nonprofit, and academic organizations could each make important and unique contributions to this endeavor. This workshop examined opportunities to enhance and foster PPPsfor clinical cancer research and considered lessons learned from examples of public-private collaborations in oncology or other fields that have helped to advance clinical research and improve patient outcomes.

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Collaborative workshop co-hosted by:

National Cancer Policy Forum
American Society of Clinical Oncology

October 5-6, 2023

2023 marked the 10-year anniversary of the Institute of Medicine report *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis* and the ability of the cancer care delivery system to provide high-quality cancer care to all patients remains elusive. This workshop provided an opportunity for the cancer care community to discuss persistent barriers to achieving excellent and equitable cancer care for all and additional actions that could be taken to implement the 2013 recommendations. Workshop presentations and discussions also identified aspects of cancer care that have changed over the past decade and where new strategies are needed to improve the quality of care.

Forum Sponsors

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Cancer Care Centers

AVEO Oncology

Cancer Center at Illinois

Flatiron Health

Lilly

Merck

National Comprehensive Cancer Network

Novartis Oncology

Oncology Nursing Society

Partners In Health

Patient Advocate Foundation

Pfizer Inc.

Vibrent Health

Forum Members

Robert A. Winn, M.D. (*Chair*)
Virginia Commonwealth University

Laleh Amiri-Kordestani. M.D.
U.S. Food and Drug Administration

Rohit Bhargava, Ph.D.
Cancer Center at Illinois

Smita Bhatia, M.D., M.P.H.
University of Alabama at Birmingham

Gideon Blumenthal, M.D.
Merck

Edgar E. Braendle, M.D., Ph.D.
AVEO Oncology

Christina Chapman, M.D.
Baylor College of Medicine

Gwen Darien, B.A.
Patient Advocate Foundation

Crystal Denlinger, M.D., FACP
National Comprehensive Cancer Network

James H. Doroshow, M.D.
National Cancer Institute

S. Gail Eckhardt, M.D., FASCO
Baylor College of Medicine

Christopher R. Friese, Ph.D., R.N.,
AOCN® University of Michigan

Scarlett Lin Gomez, M.P.H., Ph.D.
University of California, San Francisco

Julie R. Gralow, M.D., FACP, FASCO
American Society of Clinical Oncology

Sarah M. Greene, M.P.H.
Cancer Research Advocate

Roy S. Herbst, M.D., Ph.D.
Yale University

Hedvig Hricak, M.D., Ph.D., Dr.h.c^{m}
Memorial Sloan Kettering Cancer Center

Chanita Hughes-Halbert, Ph.D.
University of Southern California

Roy A. Jensen, M.D.
University of Kansas; Association of American Cancer Institutes

Praduman Jain, M.S.
Vibrent Health

Randy A. Jones, Ph.D., R.N., FAAN
University of Virginia

Beth Y. Karlan, M.D.
University of California, Los Angeles

Nancy L. Keating, M.D., M.P.H.
Harvard Medical School

Samir N. Khleif, M.D.
Georgetown University

Ronald Kline, M.D.
Centers for Medicare and Medicaid Services

Shivaani Kummar, M.D., FACP
Oregon Health and Science University

Jeff Legos , Ph.D.
Pfizer Inc.

Elena Martinez, Ph.D.
University of California, San Diego

Larissa Nekhlyudov, M.D., M.P.H., FASCO
Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School

Cleo A. Ryals, Ph.D.
Flatiron Health

Susan M. Schneider, Ph.D., R.N., AOCN®
Duke University

Lawrence N. Shulman, M.D., MACP, FASCO
University of Pennsylvania

Michelle Sidel, Ph.D.
Novartis Pharmaceuticals

Amye J. Tevaarwerk, M.D.
Mayo Clinic in Rochester, Minnesota

Katrina Trivers, Ph.D., M.S.P.H.
Centers for Disease Control and Prevention

Megan Tweed, M.P.P
Lilly

Robin Yabroff, Ph.D.
American Cancer Society

Forum Staff

RESPONSIBLE STAFF OFFICERS

Francis Amankwah, M.P.H.
Forum Director

Sharyl Nass, Ph.D.
Senior Program Director, Health Care and Public Health

ADDITIONAL PROJECT STAFF

Anna Adler, M.P.H.
Research Associate

Torrie Brown, B.A.
Program Coordinator

Makeda Haughton, B.A.
Senior Program Assistant

Julie Wiltshire, B.S.
Senior Finance Business Partner

NATIONAL ACADEMIES *Sciences Engineering Medicine*

The National Academies provide independent, trustworthy advice that advances solutions to society's most complex challenges.
www.nationalacademies.org

CONTACT: Francis Amankwah ☒ famankwah@nas.edu
Health Care and Public Health
Center for Health, People, and Places

NATIONAL ACADEMIES Sciences Engineering Medicine

Workshop Proceedings and Proceedings—in Brief



2026

Innovative Person-Centered Clinical Cancer Research: Proceedings of a Workshop—in Brief

2025

Strategies and Interventions to Strengthen Support for Family Caregivers for Individuals with Serious Illness or Disability: Proceedings of a Workshop—in Brief

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

Exploring Clinical Guidelines for the Adoption of Genomic Testing

Enabling 21st Century Applications for Cancer Surveillance through Enhanced Registries and Beyond

2024

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

Optimizing Public-Private Partnerships for Clinical Cancer Research

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Developing a Multidisciplinary and Multispecialty Workforce for Patients with Cancer, from Diagnosis to Survivorship

Incorporating Integrated Diagnostics into Precision Oncology Care

Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics

2023

The Potential Contribution of Cancer Genomics Information to Community Investigations of Unusual Patterns of Cancer

Advancing Progress in Cancer Prevention and Risk Reduction

Realizing the Potential of Genomics across the Continuum of Precision Health Care



2022

Family Caregiving for People with Cancer and Other Serious Illnesses

Innovation in Electronic Health Records for Cancer Care, Research, and Surveillance

Promoting Health Equity in Cancer Care

The Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and Cancer Susceptibility in Humans

Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: Impact of the Affordable Care Act on Cancer Prevention and Cancer Care

NATIONAL CANCER POLICY FORUM

To receive updates on the National Cancer Policy Forum, visit: nationalacademies.org/NCPF or #NatlCancerForum





2021

Addressing the Adverse Consequences of Cancer Treatment

Opportunities and Challenges for Using Digital Health Applications in Oncology

Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer

Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening

Drug Research and Development for Adults Across the Older Age Span

2020

Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward

Applying Big Data to Address the Social Determinants of Health in Oncology

Health Literacy and Communication Strategies in Oncology

Enhancing Scientific Reproducibility in Biomedical Research Through Transparent Reporting

2019

Developing and Sustaining an Effective and Resilient Oncology Careforce

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Improving Cancer Diagnosis and Care: Clinical Application of Computational Methods in Precision Oncology

2018

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies

Establishing Effective Patient Navigation Programs in Oncology

Long-Term Survivorship Care After Cancer Treatment

2017

The Drug Development Paradigm in Oncology

Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care

Implementation of Lung Cancer Screening

Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum

2016

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop

Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary

Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary

2015

Comprehensive Cancer Care for Children and Their Families

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

Assessing and Improving the Interpretation of Breast Images

Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research









2014

Ensuring Patient Access to Affordable Cancer Drugs

Contemporary Issues for Protecting Patients in Cancer Research

2013

Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer

Implementing a National Cancer Clinical Trials System for the 21st Century

Sharing Clinical Research Data

Delivering Affordable Cancer Care in the 21st Century

Reducing Tobacco-Related Cancer Incidence and Mortality

2012

The Role of Obesity in Cancer Survival and Recurrence

Informatics Needs and Challenges in Cancer Research

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies

2011

Implementing a National Cancer Clinical Trials System for the 21st Century

Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care

The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care

Nanotechnology and Oncology

2010

Direct-to-Consumer Genetic Testing (with the National Research Council)

Extending the Spectrum of Precompetitive Collaboration in Oncology Research

A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care

Policy Issues in the Development of Personalized Medicine in Oncology

2009

Assessing and Improving Value in Cancer Care

Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century

Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program

2008

Implementing Colorectal Cancer Screening

Improving the Quality of Cancer Clinical Trials

2007

Cancer-Related Genetic Testing and Counseling

Cancer in Elderly People

Implementing Cancer Survivorship Care Planning

2006

Effect of the HIPAA Privacy Rule on Health Research

Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment









Related Work

CONSENSUS STUDY REPORTS BUILDING ON NCPF WORK

Childhood Cancer and Functional Impacts Across the Care Continuum (2021)
Report: nap.edu/catalog/25944

Diagnosing and Treating Adult Cancers and Associated Impairments (2021)
Report: nap.edu/catalog/25956

Guiding Cancer Control: A Path to Transformation (2019)
Report: nap.edu/catalog/25438

Making Medicines Affordable: A National Imperative (2017)
Report: nap.edu/catalog/24946

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine (2016)
Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)
Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)
Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)
Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)
Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)
Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)
Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)
Report: nap.edu/read/11892

INDIVIDUALLY AUTHORED PUBLICATIONS BUILDING ON NCPF WORK

Independent, individually authored articles arising from NCPF workshops—and consensus studies building on NCPF work—include:

2026

- Amankwah, F. K., J. Zhu, S. Bhatia, G. Darien, S. Greene, L. Nekhlyudov, L. N. Shulman, R. A. Winn, and S. J. Nass. 2026. The national cancer policy forum: A strong voice for improving cancer care and outcomes. *JNCI: Journal of the National Cancer Institute*:djag030.

2025

- Shulman, L. N., H. Hricak, and S. G. Eckhardt. 2025. Challenges and opportunities for the US oncology workforce. *JAMA Oncology*. 10.1001/jamaoncol.2025.2331.
- Shulman, L. N., C. J. Bradley, R. A. Winn, and K. R. Yabroff. 2025. Cancer surveillance in the United States in jeopardy: Leveraging 21st century technology to enhance public health. *Journal of Clinical Oncology:-JCO* 2500754.

2024

- Herbst, R. S., G. Blumenthal, S. N. Khleif, S. M. Lippman, N. J. Meropol, K. Rosati, L. N. Shulman, H. Smith, M. Wang, R. A. Winn, and R. L. Schilsky. 2024. Optimizing public private partnerships to support clinical cancer research. *Journal of the National Cancer Institute*. 10.1093/jnci/djae279
- Nekhlyudov, L., L. A. Levit, and P. A. Ganz. 2024. Delivering high-quality cancer care: Charting a new course for a system in crisis: One decade later. *Journal of Clinical Oncology.* 42(36):4342-4351.
- Peterson, D. E., N. L. Stout, L. N. Shulman, J. Perkins, G. LeMarier, and L. Nekhlyudov. 2024. Gaps in access to medically necessary dental care for patients living with and beyond cancer: We must do better. *Journal of Clinical Oncology.* https://doi.org/10.1200/JCO.24.00162.
- Singh, A. P., E. P. Balogh, R. W. Carlson, M. M. Huizinga, B. A. Malin, A. Melamed, N. J. Meropol, E. D. Pisano, R. A. Winn, K. R. Yabroff, and L. N. Shulman. 2024. Re-envisioning electronic health records to optimize patient-centered cancer care, quality, surveillance, and research. *Journal of Clinical Oncology: Oncology Practice.* 10.1200/OP.24.00260.

2022

- Bono, K. and N. L. Keating. 2022. Addressing social determinants of health: Now is the time. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac137/6705076?searchresult=1.
- Bradley, C. J., S. Kitchen, S., Bhatia , J. Bynum, G. Darien, J. L. Lichtenfeld, R. Oyer, L. N. Shulman, and L. Kennedy Sheldon. 2022. Policies and practices to address cancer's long-term adverse consequences. *Journal of the National Cancer Institute.* 114(8):1065-1071. https://academic.oup.com/jnci/article-abstract/114/8/1065/6570605?redirectedFrom=fulltext.
- Davidson, N. E., K. E. Knudsen, S. Fuld Nasso, R. Oyer, S. Pergam, L. Strawbridge, and L. Shulman. 2022. Cancer care at the beginning of the COVID-19 pandemic: Effects on patients and early interventions to mitigate stresses on care. *Cancer Journal* 28(2):107-110. https://journals.lww.com/journalppo/Abstract/2022/03000/Cancer__Care__at__the__Beginning__of__the__COVID__19.5.aspx.
- Fan, Q, D. Keene, M. Banegas, S. Gehlert, L. M. Gottlieb, K. R. Yabroff, C. E . Pollack. 2022. Housing insecurity among patients with cancer. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/article/114/12/1584/6705075.
- Graboyes, E. M., K. H. Chaiyachati, J.S. Gall, W. Johnson, J. S. Krishnan, S. S. McManus, L. Thompson, L. N. Shulman, K. R. Yabroff. 2022. Addressing transportation insecurity among patients with cancer. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac134/6705073?searchresult=1.
- Hyer, R. N. 2022. Insights for oncology trials garnered from the rapid development of an mRNA COVID-19 vaccine. *Cancer Journal* 28(2):146-150. https://journals.lww.com/journalppo/Fulltext/2022/03000/Insights__for__Oncology__Trials__Garnered__From__the.12.aspx.
- Karzai, F., and W. L. Dahut. 2022. Lessons from the impact of the COVID-19 pandemic at the national cancer institute: Cancer research and care. *Cancer Journal* 28(2):118-120. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons__From__the__Impact__of__the__COVID__19__Pandemic.7.aspx.
- Nekhlyudov, L., L. A. Fleisher, and P. B. Jacobsen. 2022. Telemedicine across the cancer care continuum: Evidence and opportunities for clinical care, research, and policy. *Cancer Journal* 28(2):121-124. https://journals.lww.com/journalppo/Abstract/2022/03000/Telemedicine__Across__the__Cancer__Care__Continuum__.8.aspx.
- Nekhlyudov L., G. B. Campbell., K. H. Schmitz, G.A. Brooks, A.J. Kumar, P.A. Ganz, and D. Von Ah 2022. Cancer-related impairments and functional limitations among long-term cancer survivors: Gaps and opportunities for clinical practice. *Cancer* 128(2): 222-229. https://pubmed.ncbi.nlm.nih.gov/34529268/.
- Oyer, R. A., L. Pierce, C. Lathan, and B. Sagar. 2022. Maintaining and advancing quality cancer care during a global pandemic. *Cancer Journal* 28(2):134-137. https://journals.lww.com/journalppo/Abstract/2022/03000/Maintaining__and__Advancing__Quality__Cancer__Care.10.aspx.
- Parikh, R. B., K. M. Basen-Engquist, C. Bradley, D. Estrin, M. Levy, J. L. Lichtenfeld, B. Malin, D. McGraw, N. J. Meropol, R. Oyer, L. Kennedy Sheldon, and L. N. Shulman. 2022. Digital health applications in oncology: An opportunity to seize. 2022. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac108/6596055?redirectedFrom=fulltext#-no-access-message.
- Prindiville, S. A., G. A. Sarosy, D. Loose, H. Ciolino, and J. H. Doroshow. 2022. Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at national cancer institute-designated cancer centers. *Cancer Journal* 28(2):111-117. https://journals.lww.com/journalppo/Abstract/2022/03000/Patterns__of__Enrollment__in__Cancer__Treatment__Trials.6.aspx.
- Raber, M., A. Jackson, K. Basen-Engquist, C. Bradley, S. Chambers, F. N. Gany, C. Hughes-Halbert, S. T. Lindau, R. Perez-Escamilla, and H. Seligman. 2022. Food insecurity among people with cancer: Nutritional needs as an essential component of care. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac135/6705074?searchresult=1..
- Rivera, D. R., P. G. Kluetz, K. Abdallah, S. Agrawal, D. C. Angus, R. M. Califf, E. Garrett-Mayer, R. Hyer, D. R. Lowy, and S. N. Khleif. 2022. Clinical evidence generation during a pandemic: Lessons learned for sustaining progress. *Cancer Journal* 28(2):151-156. https://journals.lww.com/journalppo/Abstract/2022/03000/Clinical__Evidence__Generation__During__a__Pandemic__.13.aspx .
- Roberts, T. J., and I. T. Lennes. 2022. Lessons for oncology from the COVID-19 pandemic: Operationalizing and scaling virtual cancer care in health systems. *Cancer Journal* 28(2):125-133. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons__for__Oncology__From__the__COVID__19__Pandemic__.9.aspx.

- Schilsky, R. L. 2022. Beyond the COVID-19 pandemic: Sustaining and improving equitable cancer care and research. *Cancer Journal* 28(2):105-106. https://journals.lww.com/journalppo/Citation/2022/03000/Beyond_the_COVID_19_Pandemic___Sustaining_and.4.aspx.
- Winkfield, K. M., and R. A. Winn. 2022. Improving equity in cacer care in the face of a publice health emergency. Cancer Journal 28(2):128-145. https://journals.lww.com/journalppo/Abstract/2022/03000/Improving_Equity_in_Cancer_Care_in_the_Face_of_a.11.aspx

2021

- Bertagnolli, M. M. and H. Singh. 2021. Treatment of older adults with cancer - Addressing gaps in evidence. *New England Journal of Medicine* 385:1062-1065. https://www.nejm.org/doi/full/10.1056/NEJMp2106089.
- Housten, A. J., C. M. Gunn, M. K. Paasche-Orlow, and K. M. Basen-Engquist. 2021. Health literacy interventions in cancer: A systematic review. *Journal of Cancer Education* 36(2):240-252. https://pubmed.ncbi.nlm.nih.gov/33155097/.

2020

- Schilsky, R.L., S. Nass, M.M. Le Beau, and E. J. Benz, Jr. 2020. Progress in cancer research, prevention, and care. *New England Journal of Medicine* 383(10):897-990. https://www.nejm.org/doi/full/10.1056/NEJMp2007839.
- Shulman, L. N., L. Kennedy Sheldon, and E. J. Benz. 2020. The future of cancer care in the United States—Overcoming workforce capacity limitations. *JAMA Oncology* 6(3):327-328. https://jamanetwork.com/journals/jamaoncology/article-abstract/2758839..
- Panagiotou, O. A., L. Hoffman-Högg, H. Hricak, S. N. Khleif, M. A. Levy, D. Magnus, M. J. Murphy, B. Patel, R. A. Winn, S. J. Nass, C. Gatsonis, and C. R. Cogle. 2020. Clinical application of computational methods in precision oncology: A review. *JAMA Oncology* 6(8):1282:1286. https://jamanetwork.com/journals/jamaoncology/article-abstract/2765757.

2019

- Balogh, E. P., A. B. Bindman, S. G. Eckhardt, S. Halabi, R. D. Harvey, I. Jaiyesimi, R. Miksad, H. L. Moses, S. J. Nass, R. L. Schilsky, S. Sun, J. M. Torrente, and K. E. Warren. 2019. Challenges and opportunities to updating prescribing information for longstanding oncology drugs. *The Oncologist 24*:1-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/.
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Högg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. Kennedy Sheldon, and L. N. Shulman. 2019. Developing and sustaining an effective and resilient oncology careforce: Opportunities for action, *Journal of the National Cancer Institute* 112(7):663-670. https://doi.org/10.1093/jnci/djz239.
- Kline, R. M., G. B. Rocque, E. A. Rohan, K. A. Blackley, C. A. Cantril, M. L. Pratt-Chapman, H. A. Burris, and L.N Shulman. 2019. Patient navigation in cancer: The business case to support clinical needs. *Journal of Oncology Practice* 15(11):585-590. https://www.ncbi.nlm.nih.gov/pubmed/31509483.
- Lubejko, B. G., C. Cantril, L. H. Hogg, and L. Kennedy Sheldon. 2019. Novice oncology nurse navigator: Core elements in establishing training needs and building on competencies. *Clinical Journal of Oncology Nursing* 23(4):387-394. https://www.ncbi.nlm.nih.gov/pubmed/31322621.
- Nass, S. J., M.B. Cohen, R. Nayar, M.M. Zutter, E. P. Balogh, R. L. Schilsky, H. Hricak, and K.S.J. Elenitoba-Johnson. 2019. Improving cancer diagnosis and care: Patient access to high-quality oncologic pathology. *The Oncologist* 24(10):1287-1290. https://www.ncbi.nlm.nih.gov/pubmed/31366725.
- Lopez, D., M. L. Pratt-Chapman, E. A. Rohan, L. Kennedy Sheldon, K. Basen-Engquist, R. Kline, L. N. Shulman, and E. J. Flores. 2019. Establishing effective patient navigation programs in oncology. *Supportive Care in Cancer* 27(6):1985-1996. https://www.ncbi.nlm.nih.gov/pubmed/30887125.
- Nass, S. J., C. R. Cogle, J. A. Brink, C. P. Langlotz, E. P. Balogh, A. Muellner, D. Siegal, R. L. Schilsky, and H. Hricak. 2019. Improving cancer diagnosis and care: Patient access to oncologic imaging expertise. *Journal of Clinical Oncology* 37(20):1690-1694. https://www.ncbi.nlm.nih.gov/pubmed/31050908.

2018

- Kline, R. M., N. K. Arora, C. J. Bradley, E. R. Brauer, D. L. Graves, N. Buchanan Lunsford, M. S. McCabe, S. F. Nasso, L. Nekhlyudov, J. H. Rowland, R. M. Schear, and P. A. Ganz. Long-term survivorship care after cancer treatment—summary of a 2017 National Cancer Policy Forum workshop. *Journal of the National Cancer Institute* 110(12):1300-1310. https://www.ncbi.nlm.nih.gov/pubmed/30496448.
- Nass, S. J., M. Rothenberg, R. Pentz, H. Hricak, A. Abernethy, K. Anderson, A. W. Gee, R.D. Harvey, S. Piantadosi, M. M. Bertagnolli, D. Schrag, and R. L. Schilsky. Accelerating anticancer drug development—opportunities and trade-offs. *Nature Reviews Clinical Oncology* 15(12):777-786. https://www.ncbi.nlm.nih.gov/pubmed/30275514.
- Demark-Wahnefried, W., K. H. Schmitz, C. M. Alfano, J. R. Bail, P. J. Goodwin, C. A. Thomson, D. W. Bradley, K. S. Courneya, C. A. Befort, C. S. Denlinger, J. A. Ligibel, W. H. Dietz, M. R. Stolley, M. L. Irwin, M. M. Bamman, C. M. Apovian, B. M. Pinto, K. Y. Wolin, R. M. Ballard, A. J. Dannenberg, E. G. Eakin, M. M. Longjohn, S. D. Raffa, L. L. Adams-Campbell, J. S. Buzaglo, S. J. Nass, G. M. Massetti, E. P. Balogh, E. S. Kraft, A. K. Parekh, D. M. Sanghavi, G. S. Morris, and K. Basen-Engquist. 2018. Weight management and physical activity throughout the cancer care continuum. *CA: A Cancer Journal for Clinicians* 68(1):64-89. https://www.ncbi.nlm.nih.gov/pubmed/29165798.

2017

- Basen-Engquist, K., C. M. Alfano, M. Maitin-Shepard, C. A. Thomson, K. H. Schmitz, B. M. Pinto, K. Stein, D. S. Zucker, K. L. Syrjala, E. Fallon, C. Doyle, and W. Demark-Wahnefried. 2017. Agenda for translating physical activity, nutrition, and weight management interventions for cancer survivors into clinical and community practice. *Obesity* (Silver Spring) 25(Suppl 2):S9-S22. https://www.ncbi.nlm.nih.gov/pubmed/29086526.

- Smith, G. L., P. A. Ganz, J. E. Bekelman, S. J. Chmura, J. J. Dignam, J. A. Efstathiou, R. Jagsi, P. A. Johnstone, M. L. Steinberg, S. B. Williams, J. B. Yu, A. L. Zietman, R. R. Weichselbaum, and Y.-C. Shih. 2017. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy Forum workshop. *International Journal of Radiation Oncology • Biology • Physics* 97(3):450-461. https://www.ncbi.nlm.nih.gov/pubmed/28011046.

2016

- Kirch, R., G. Reaman, C. Feudtner, L. Wiener, L. A. Schwartz, L. Sung, and J. Wolfe. 2016. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine workshop highlights and next steps. *CA: A Cancer Journal for Clinicians* 66(5):398-407. https://www.ncbi.nlm.nih.gov/pubmed/27145249.

2015

- Nass, S. J., L. K. Beaupin, W. Demark-Wahnefried, K. Fasciano, P. A. Ganz, B. Hayes-Lattin, M. M. Hudson, B. Nevidjon, K. C. Oeffinger, R. Rechis, L. C. Richardson, N. L. Seibel, and A. W. Smith. 2015. Identifying and addressing the needs of adolescents and young adults with cancer: Summary of an Institute of Medicine workshop. *Oncologist* 20(2):186-195. https://www.ncbi.nlm.nih.gov/pubmed/25568146.

2014

- Bertagnolli, M. M., R. Canetta, and S. J. Nass. 2014. Expanding public-private collaborations to enhance cancer drug development: A Report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century." *Oncologist* 19(11):1179-1185. https://www.ncbi.nlm.nih.gov/pubmed/25326161.

- Balogh, E. P., C. Dresler, M. E. Fleury, E. R. Gritz, T. J. Kean, M. L. Myers, S. J. Nass, B. Nevidjon, B. A. Toll, G. W. Warren, and R. S. Herbst. 2014. Reducing tobacco-related cancer incidence and mortality: Summary of an Institute of Medicine workshop. *Oncologist* 19(1):21-31. https://www.ncbi.nlm.nih.gov/pubmed/24304712.

- Ferrell, B. R., T. J. Smith, L. Levit, and E. Balogh. 2014. Improving the quality of cancer care: Implications for palliative care. *Journal of Palliative Medicine* 17(4):393-399. https://www.ncbi.nlm.nih.gov/pubmed/24548217.

2013

- Ramsey, S. D., P. A. Ganz, V. Shankaran, J. Peppercorn, and E. Emanuel. 2013. Addressing the American health-care cost crisis: Role of the oncology community. *Journal of the National Cancer Institute* 105(23):1777-1781. https://www.ncbi.nlm.nih.gov/pubmed/24226096.

- Balogh, E. P., P. B. Bach, P. D. Eisenberg, P. A. Ganz, R. J. Green, J. C. Gruman, S. J. Nass, L. N. Newcomer, S. D. Ramsey, J. E. Schottinger, and Y. T. Shih. 2013. Practice-changing strategies to deliver affordable, high-quality cancer care: Summary of an Institute of Medicine workshop. *Journal of Oncology Practice* 9(6s):54s-59s. https://www.ncbi.nlm.nih.gov/pubmed/29431037.

NATIONAL ACADEMIES Sciences Engineering Medicine

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

Purpose

To prohibit discrimination, harassment, and bullying for all participants in National Academies activities.

Applicability

All participants in all settings and locations in which the National Academies work and activities are conducted.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

The National Academies of Sciences, Engineering, and Medicine (National Academies) are committed to the principles of integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. **All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity.** This policy applies to all participants in all settings and locations in which the National Academies work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Definitions

Discrimination is prejudicial treatment of individuals or groups of people based on their race, color, national origin, sex, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.
Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.
Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.
Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Reporting and Resolution

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual at the time the incident occurs, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint through the National Academies Complaint Intake Form (https://nas.hracuity.net/webform/index/a5ed0226-f5e5-4da4-be0d-1daf8976f594), and/or
- Filing a complaint with the Office of Human Resources at 202-334-3400 or hrservicecenter@nas.edu, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.
If an investigation results in a finding that an individual has committed a violation, the National Academies will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances **the removal of an individual from current National Academies activities and a ban on participation in future activities**.

Confidentiality

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. The National Academies will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Responsible Party

The NRC Executive Officer is responsible for oversight of and substantive changes to the policy.

Revised: 01/28/2025